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Abstract 
Antibodies have a unique ability to bind to a wide variety of different molecules, 
ranging from large protein antigens to low molecular weight organic molecules. 
The specificity and affinity of the binding varies between antibodies and can be 
utilised in many applications. Recombinant antibody fragments have advantages 
over traditional poly- and monoclonal antibodies in production and 
immobilisation and in the optimisation of their properties. 
Enantiomers of a chiral compound provide a challenge for separation methods 
and analytics due to their similar chemical and physical properties. Antibodies 
provide a highly specific way to fractionate enantiomers in both preparative and 
analytical applications. 
In this work two different antibody-based approaches to separate enantiomers of 
a chiral drug candidate were developed. Antibody fragments were cloned, 
produced in bacteria and immobilised on a solid affinity support. Repeated 
affinity purification of enantiomers was achieved in optimised conditions. In the 
other approach antibody fragments were immobilised inside the nanotubes of an 
alumina membrane and the bionanomembrane was used to fractionate 
enantiomers of a racemic mixture. 
In addition a sample preparation method, antibody-based solid-phase extraction, 
was developed in a way that can be applied to high-throughput format. 
Recoveries were comparable to those reported for non-specific sorbents, but 
with the advantage of the enantioselectivity. The method was used to extract an 
enantiomer from a spiked buffer or serum. The preparatory sample treatment 
protocols usually used for serum, e.g. protein precipitation, were not needed. 
A homology model of one of the antibody fragments was constructed and used 
to design site-specific mutations in order to adjust the affinity of the antibody to 
be suitable for the preparative and analytical approaches developed in this work. 
One of the mutants, ENA5His Tyr96Val, had appropriate properties both in 
preparative and analytical applications. 
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1. Introduction 
1.1 Chirality 
Life is dependent on the chirality of molecules. Chirality is a spatial property of 
a molecule and is determined by the three-dimensional arrangement of its atoms 
(from the Greek word cheir meaning hand, handedness). Amino acids and 
carbohydrates, the building blocks of proteins and of polysaccharides and DNA, 
respectively, are chiral compounds. Therefore most biological functions are 
asymmetric, favouring only one chiral form of the molecule. Chirality is an 
efficient way to increase the specificity of recognition, binding, catalysis and 
other biological events. 
Applied sciences, e.g. pharmaceutical, forensic, environmental and food 
sciences, have shown increasing interest in chirality due to the increased 
exposure of humans to synthetic chiral chemicals such as medical and illegal 
drugs and pesticides. The stereochemical properties of chiral compounds in 
foods, fragrances and agrochemicals in both natural and work environments 
have increasingly attracted attention (Armstrong and Zhang, 2001, Müller and 
Kohler, 2004). When a chiral compound enters a living organism, a chiral 
distinction occurs in physiological processes. Different forms of a chiral 
compound, stereoisomers (Figure 1), have different interactions with the target 
molecules, such as receptors, ion channels, transporters and enzymes. Although 
scientists have known the phenomenon of chirality from the middle of the 
nineteenth century when Pasteur performed his experiments with tartaric acid, 
deeper awareness was not aroused until 1960s when the first indications of the 
chiral compound thalidomide as a cause of miss-shaped fetuses emerged. 
1.1.1 Enantiomers 
Distinctive for an asymmetric chiral atom is that all groups attached to it via a 
covalent bond are different. Most common is a carbon atom having four 
substituents and it is used here as an example (Figure 2 a). Organic compounds 
that have one or more such chiral atoms have stereoisomers due to the different 
spatial arrangement, configuration, of these groups. A pair of non-
  14 
superimposable mirror images of a chiral compound is a pair of enantiomers 
(form the Greek enantios, opposite) (Figure 1). 
 
Figure 1. Definitions of stereoisomers and the relationships between them. 
The designation (S) (lat. sinister = left) or (R) (lat. rectus = right) is used to 
express the configuration of the groups bonded to the chiral atom. The absolute 
configuration around the chiral atom is the order of the arrangement of the four 
different groups. The groups have priorities according to their atomic number. 
The lowest-priority substituent is placed behind the stereogenic centre and if an 
imaginary arrow drawn from the highest to the second highest priority group is 
clockwise then the configuration is R, contrary to the S configuration. The 
compound has a maximum of 2n optical isomers, where n is the number of chiral 
atoms. Enantiomers have the same physical and chemical properties and they are 
difficult to separate from each other by any chemical or physical means. They 
differ only in the way they react with other chiral compounds, such as target 
proteins (Figure 2 b), and how they rotate polarized light. 
 
 
 
 
Stereoisomers
Molecules that have same stochiometric molecular formula
and identical constitution. Arrangement of their atoms differ
in space.
Enantiomers
Non-superimposable mirror images of
each other. Chemically and physically identical.
Different interactions in chiral environments
Diastereomers
Not related as mirror images.
Different physical and chemical properties
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a.                                      b. 
Figure 2. a) A chiral carbon atom with four different substituents: the amino 
acid alanine as an example. b) Enantiomers are non-superimposable mirror 
images of each other. The spatial arrangement of different substituents varies 
between enantiomers and therefore only one of the enantiomers is a perfect fit 
with the binding surface of the target protein. (Modified from Guzman and 
Stubbs, 2001) 
Configuration does not reveal the light rotating direction and therefore a full 
description of the chiral compound often also includes a light rotating 
characteristic d/l or +/-, respectively. The enantiomer which rotates the light to 
the left is designated by () or l (levorotatory), or to the right (+) or d 
(dextrorotatory). When the solution has equal amounts of enantiomers it is 
optically inactive. A mixture having an equal amount of enantiomers is called a 
racemate. Enantiomeric excess ranging 0100% is used to describe the relative 
amounts of enantiomers in the mixture from racemate to pure single enantiomer, 
respectively. 
C C
BINDING SURFACE
ONE ENANTIOMER OTHER ENANTIOMER
NO FIT
NO BINDING
SPECIFIC
BINDING
MIRROR
BINDING SURFACE
C
COOHNH2
CH3 H
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1.1.2 Chiral compounds in humans: the example of drugs 
In most cases the enantiomers of a drug differ in their activities in the human 
body. Enantioselective differences are not only due to the interactions between 
the drug and its pharmacological receptor but also to its pharmacokinetic 
properties including absorption, unspecific protein binding, transport, 
metabolism and excretion. 
Figure 3 illustrates the complexity of the different routes of the two enantiomers. 
After administration the two enantiomers may differ in both their route and their 
rate of absorption and distribution. The enantiomers may also differ 
quantitatively in their action with the pharmacological receptor. The active 
enantiomer is called a eutomer and the less or non-active enantiomer a distomer. 
Enantiomers may also have qualitative differences and thus distinctly different 
biological activities. Many of the side effects of chiral drugs are caused by the 
distomer, which has activity towards another target. Some examples of the 
effects of distomers are listed in Table 1. 
Figure 3. A graphical illustration of the possible complexity of the action of the two 
enantiomers  S and R in vivo. In addition to the different sites of action, their efficiency 
can vary and competition between the enantiomers may occur. S1-Sn and R1-Rn reflect 
the unknown number of metabolites of the S and R enantiomers, respectively. 
 
Metabolism
Target
Excretion
Side-effect
Other target
Toxic
S1-Sn R1-Rn
absorption and distribution
S R
S R
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Table 1. Examples of the effects of distomers of drugs. 
EFFECT OF THE DISTOMER EXAMPLE REFERENCE
Lower activity Methoxychlor metabolites Miyashita et al ., 2004
Warfarin Takahashi and 
Opposite activity Albuterol Nelson et al. , 1998
(R )- Bronchodilatory, anti-asthmatic
(S )- enhances airway hypersensitiveness
Separate activity Dexanabinol Knoller et al. , 2002
(-)- cannabinoid activity
(+)- neuroprotective agent, no cannabinoid activity 
Undesirable activity ketamine White et al ., 1980
(S )-(+)-anesthetic, analgesic
(R )-(-)- hallucinations, agitation
Echizen, 2001
 
The greatest degree of stereoselectivity is introduced into the drug disposition by 
drug metabolism. Enantioselectivity in absorption and distribution is 
substantially lower (reviewed by Caldwell, 1995). The administered drug is a 
foreign substance and metabolism is a way to eliminate it. The mechanism has 
evolved to remove potentially harmful organic molecules from the body. Low 
molecular weight compounds are chemically modified to be excreted more 
efficiently. Usually excretion is enhanced by increasing the solubility of the 
compound. The same enzyme may metabolise both enantiomers but with 
different rates, or the enantiomers may be metabolised by different enzymes 
(reviewed by Rentsch, 2002). In some cases the metabolite may have even 
higher activity than the drug itself and much interest has arisen concerning the 
use of the metabolites as drugs. On the other hand metabolism may be harmful, 
e.g. by increasing the toxicity of the compound. An example of problematic 
metabolism is racemic ibuprofen, a non-steroidal anti-inflammatory drug, which 
is stereospecifically conjugated with glucuronic acids. Conjugation can lead to 
attachment of the ibuprofen to proteins in vivo. Preliminary evidence suggests 
that such a covalent modification of native proteins by ibuprofen can cause 
allergic reactions and hepatotoxicity (Ikegawa et al., 2001, Ito et al., 2004). 
The fact that the behaviour of the enantiomers in racemic mixtures is different 
than would be expected from their individual properties makes the issue even 
more complicated. The relationships between eutomers and distomers cannot 
easily be predicted and they must therefore be experimentally established. For 
example the side effect of (+)-indacrinone is the retention of uric acid. The other 
enantiomer antagonises it and the optimal therapeutic profile is obtained with a 
1:4 or 1:8 ratio of isomers (Tobert, 1981). There are also cases in which co-
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administration of the inactive enantiomer may increase the free plasma 
concentration of the active enantiomer by reducing its plasma binding, 
metabolism or excretion (Lloyd, 1997). In such cases it would be advantageous 
to administer both enantiomers. However, much effort is needed to study the 
non-racemic mixtures of enantiomers because at the moment the therapeutic 
effects can only be determined experimentally. Additional costs reduce the 
viability of such non-racemic mixtures. 
In some cases the pure enantiomer undergoes racemisation in vivo, as in the 
example of thalidomide (Triggle, 1997). Although there are indications that the 
teratogenic activity is related to S-enantiomer, the administration of pure R-
enantiomer would not remove the problem due to this configurational inversion 
in patients. Unidirectional chiral inversion is also possible, as has been observed 
with ibuprofen (Ito et al., 2004). Stereoselective properties of drugs in general 
were reviewed by Triggle (1997). 
The development of new chiral technologies such as asymmetric synthesis, 
chiral separations and analytics in the 1980s led to the new guidelines of FDA 
(Food and Drug Administration, 1992) for chiral drugs. The FDA guidelines 
state that regardless of whether a racemate or a single enantiomer is the ultimate 
drug, the chemical, pharmacological, pharmacokinetic and toxicological 
properties of both enantiomers must be documented. The possible racemisation 
in vivo must also be determined. 
Drugs derived from natural sources are usually single enantiomers because of 
the enzymatic and thus chiral synthesis. Palytoxin, isolated from Hawaiian coral, 
has tens of chiral centres and represents one of the most extreme examples 
(Moore and Bartolini, 1981). Stereoselective synthesis of such complex 
molecules by chemical means can be very difficult, although recent method 
development of asymmetrical synthesis has been rapid, including enzymatic 
catalysis. In practice most of the synthetic drugs do not contain so many chiral 
centres. Of the new drugs approved by FDA (19912002), 42% had no chiral 
centre, 14% were racemates and 44% single enantiomers. Of the single 
enantiomer drugs 3.5% had only one chiral centre and the rest had multiple 
centres (Caner et al., 2004). During recent years the number of racemates 
introduced as new drug entities has been decreasing. Old drugs, however, can 
still be marketed as mixtures of even several stereoisomers (Goel et al., 2004). 
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Chiral switches are drugs that have already been approved as racemates but have 
since been redeveloped as single enantiomers. By chiral switching a 3-year 
extension for the patent protection of the compound can be obtained. This 
benefit has increased the interest in re-studying the enantiomers of old drugs. For 
a review and examples of chiral switches see Agranat et al. (2002).  
According to Caner et al. (2004) drug chirality is now a major theme in the 
design, discovery, development, launching and marketing of new drugs. There is 
an increasing preference for single enantiomers due to the advantages they 
provide, such as dose reduction, less side effects and more precise estimation of 
dose-response relationships. Stereoselective aspects also help to understand the 
mechanisms of action and make it possible to optimise the safety and 
effectiveness of the drug. 
Proteins, peptides, nucleotides and oligosaccharides are also chiral molecules but 
they do not exist as racemates in vivo. In addition they have different routes of 
function and elimination from low molecular weight organic compounds and are 
therefore not included in this thesis. 
1.2 Recombinant antibodies 
1.2.1 Background 
Antibodies (immunoglobulins) are the essential component of the humoral 
immune response. They are binding proteins produced by B-lymphocytes to 
eliminate invading foreign macromolecular substances in vivo. Antibodies of 
various species and their characteristics were recently listed by Yau et al., 2003. 
The unique features of the immune system are ability to distinguish between self 
and non-self, memory, enormous diversity and specificity of recognition. The 
diversity and specificity are the most essential attributes for in vitro applications 
of antibodies. The diversity of the immune system in vivo is due to the 
combinatorial assembly of the antibody gene segments and due to the somatic 
mutations which fine-tune the binding properties of the antibodies. The 
specificity of the binding originates from the unique structural elements of the 
antibody proteins, as reviewed below. 
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Antigens are substances that can induce the production of antibodies in vivo. The 
word hapten is used to describe a small organic compound which in itself cannot 
elicit the immune response but as a protein conjugate becomes immunogenic. 
Antibody production in vivo is induced mainly by infection or by immunising 
with an immunogen. After immunisation a set of heterogeneous antibodies can 
be isolated directly from the serum. These polyclonal antibodies have different 
affinities and can recognise various sites, epitopes, of the antigen. The lack of 
reproducibility of the same sera and problems with cross-reactivity and 
backround binding are disadvantages of the polyclonal antibodies which have 
been used traditionally in immunoassays and as a research tool. Another route is 
to produce monoclonal antibodies by utilising hybridoma technology (Köhler 
and Milstein, 1975). Antibody-producing B-lymphocytes are fused with the 
myeloma cell line to create  immortal cells.  Monoclonal antibodies produced by 
these hybridoma cells have defined affinity and specificity and their production 
is reproducible. They are widely used in various diagnostic applications although 
they suffer from the restrictions of the immunisation, e.g. antibodies against self-
antigens or toxic compounds are difficult to obtain. 
Recent developments in antibody technology, utilising the power of antibody 
engineering, antibody gene libraries and various selection methods, have 
provided the possibility to by-pass the immunisation and to obtain specific 
binders even for challenging antigens and haptens. The high-throughput 
selection and scaled up production of recombinant antibody fragments in 
bacteria bring additional advantages over traditional poly- and monoclonal 
antibodies. Antibody engineering, display and selection technologies are 
reviewed in sections 1.2.5 and 1.2.6. 
1.2.2 Structural elements of antibodies 
Four polypeptides, two identical heavy chains and two identical light chains, 
form the basic structure of an antibody. One light chain is joined to one heavy 
chain and the Y-shaped structure is formed by linking the two heavy chains 
together as drawn schematically in Figure 4 a. Both heavy and light chain 
polypeptides fold into globular domains having about 110 amino acids in each 
domain. Heavy and light chains have four and two domains, respectively. The 
amino terminal domains of both chains, called variable domains, are responsible 
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of the diversity of the specific antigen binding. Constant domains (CL or CH1, 
CH2, CH3) have conserved sequences and structures among each sub-class 
(isotypes are κ or λ for the light chain and γ, µ, ε, δ or α for the heavy chain). 
The two carboxy-terminal domains of the heavy chain have different effector 
functions which are important for the cellular immune response in vivo. Hitherto 
no functional differences between the light chain isotypes have been observed.  
Immunoglobulins are classified according to the isotypes of the heavy chains 
into five major classes: IgG, IgM, IgA, IgD and IgE. In the primary response, 
after the first immunisation or infection, the IgM antibodies are the most 
abundant. IgM antibodies are pentamers of five Y-shaped immunoglobulin units. 
They usually have low intrinsic affinity for the antigen but due to their 
multivalency and avidity effect they are able to bind the antigen efficiently. In a 
secondary response, after subsequent exposure to immunogen, the antibodies of 
the IgG class become predominant. IgG antibodies have higher affinity for the 
antigen than IgM antibodies and due to their smaller size they diffuse more 
readily into extravascular spaces to neutralize the antigen. The dimeric IgA 
immunoglobulins appear e.g. in saliva, tears and in secretions of the gastro-
intestinal tract. Their task is to prevent microbes from adhering to the mucosal 
cells. The lowest amounts of immunoglobulins present in sera belong to the IgE 
class. They recognize e.g. allergenic epitopes and induce the symptoms of 
allergy. The physiological role of IgD is currently not well understood. 
Each variable domain (VH or VL) has four conserved framework sequences 
forming the barrel-like structure of two antiparallel β-sheets (Poljak et al., 
1973), a tertiary structure called immunoglobulin fold. The three hypervariable 
loops H1, H2, H3 and L1, L2, L3 for heavy and light chains, respectively, 
(Kabat and Wu, 1971) are located between these framework sequences in each 
chain (Figure 4 b). An antigen binding site is a combination of these six loops 
(complementarity determining regions, CDRs) of two variable domains. 
Framework regions have mainly a structural role in antibodies, although 
sometimes a framework residue may be in direct contact with the antigen 
(Sheriff et al.,1987, Wedemayer et al., 1997). Generally the contribution of the 
framework residues to the affinity is indirect, produced by supporting the 
structure of the CDRs (Lamminmäki et al., 1999, Daugherty et al., 2000, 
Kusharyoto et al., 2002) or by affecting the correct folding (de Haard et al., 
1998). Decrease in affinity may be caused by a single amino acid change in the 
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framework region (de Haard et al., 1998, Caldas et al., 2003). The importance of 
framework regions to the binding properties of an antibody has become evident 
in humanisation studies in which the insertion of CDRs of murine origin into a 
human framework without further engineering have caused decreased affinity 
(Foote and Winter, 1992, Saldanha et al., 1999, Caldas et al., 2003). 
A. B. 
Figure 4. a) Schematic illustration of an antibody domain structure, with IgG 
antibody as an example. The amino terminal variable domains VH and VL form 
the antigen binding site. b) A ribbon diagram model of the variable domains  
hapten complex. Framework areas are black, the loop structures responsible for 
antigen binding are grey (modelled and picture generated by Nana Munck, VTT 
Biotechnology). 
Hypervariable loops are responsible for the specific recognition of the antigen. 
They vary in length and have high sequence diversity. The distribution of 
lengths of CDRs varies between species, in particular the CDR3 of the heavy 
chain. CDR-H3 loops range from 119 and 228 residues in mouse and in 
human antibodies, respectively (Collis et al., 2003). The length of the CDRs 
makes a great contribution to the combining site topography, although the 
surface shapes cannot always be directly concluded from the length of the 
CDRs. A cavity type binding site topography is often observed in anti-hapten 
antibodies in which the small molecule is to be buried into the cavity, whereas 
groove and planar binding site topographies are typical for e.g. peptides and 
proteins, respectively (Padlan and Kabat, 1988, Wang et al., 1991, MacCallum 
et al., 1996). 
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Despite the high variability in sequence the hypervariable loops, except CDR3 
of the heavy chain, have canonical structures. (Chothia and Lesk, 1987). The 
length of the loop and certain conserved structure determining residues at CDRs 
and at the framework region determine the main-chain conformation of the 
hypervariable loop and thus the canonical structure of the loop. The critical 
amino acids at CDRs are important in packing and hydrogen bonding or have 
suitable torsion angles and they are conserved in the canonical class to which 
they belong. (Chothia and Lesk, 1987, Chothia et al., 1989, Martin and 
Thornton, 1996, Al-Lazikani et al., 1997) The hypervariable loops can be 
combined randomly but in practice only a fraction of the possible combinations 
of canonical structures of CDRs are frequently used in germline antibodies 
(Vargas-Madrazo et al., 1995). Recently some sequence-structure relationships 
have also been found for the most variable CDR3 of the heavy chain (Morea et 
al., 1997, 1998, Shirai et al.,1998, Oliva et al., 1998), which has the greatest 
variability and impact on binding of antigen in many antibodies. CDR-H3, 
together with CDR-L3, has a central position in the binding site. Randomisation 
of only the CDR-H3 has produced antibodies with different specificities both in 
vivo (Xu and Davis, 2000) and in vitro, showing the importance of CDR-H3 for 
the specificity (Hoogenboom and Winter, 1992, Nissim et al., 1994, deKruif  et 
al., 1995, Braunagel and Little, 1997, deWildt et al., 1997). 
At the hypervariable region the most variable residues are mostly in contact with 
the antigen and are called the specificity determining residues (SDRs) (Padlan et 
al., 1995). Residues in the centre of the antigen binding site are in general 
crucial for the interaction with antigen (Hawkins et al., 1993, MacCallum et al., 
1996, Tomlinson et al., 1996, Jirholt et al., 2001). During maturation, somatic 
mutations are introduced to SDRs but especially to other residues not directly 
interacting with the antigen in order to stabilise the SDRs in conformations 
favouring specific binding (Wedemayer et al., 1997). The importance of non-
contact residues in in vitro affinity maturation has also been verified in 
mutagenesis studies (Hawkins et al., 1993, Chen et al., 1995, Daugherty et al., 
2000, Short et al., 2001). At the binding region the amino acid composition is 
different from the rest of the variable domain. In general e.g. tyrosines are 
abundant at the hypervariable regions (Collis et al., 2003). Due to their unique 
chemical properties, such as their dual nature of being both hydrophobic and 
able to participate in hydrogen bonding, they are able to interact with a variety of 
antigens. One recent statistical study suggested that the differences in residue 
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composition of the CDRs of the antibodies depend to some extent on the type of 
antigen, e.g. histidines and asparagines are over-represented in hapten binders 
(Collis et al., 2003). 
Comparisons of the crystal structures of antibodies with or without the bound 
antigen suggest in many cases a structural adaptation of the antibody 
conformation in the binding event. The conformation of antigen may also 
change as a result of binding, even in small haptens (Ramsland et al., 2001). 
Structural changes in antibodies can be absent (Burks et al., 1997) or restricted 
only to subtle adjustments of side chains in CDRs, and then the binding can be 
characterised as a lock-and-key-mechanism (Arevalo et al., 1993, Braden et 
al., 1996, Wedemayer et al., 1997, Valjakka et al., 2002). An induced-fit- 
mechanism has been used to describe the binding with larger structural 
adaptation such as conformational changes in loops or alterations in the relative 
dispositions of variable domains (Bhat et al., 1990, Stanfield et al., 1993). The 
third potential mechanism of binding is based on conformational isomerism of 
the antibodies in solution. Antibodies may have different conformational stages 
in solution equilibrium and the ones having the appropriate conformation bind 
the antigen (Foote and Milstein 1994). Conformational diversity can cause 
multispecificity, where a single antibody is able to bind two different antigens or 
haptens depending on its conformational stage (James et al., 2003). 
1.2.3 Recombinant antibody fragments 
The domain structure of the antibodies (Figure 4 a.) makes them especially 
suitable for genetic engineering. Fab-fragments consist of the intact light chain 
(VLCL) and the variable (VH) and the first constant domain (CH1) of the heavy 
chain. A disulphide bridge links the chains covalently together. The first report 
of the production of a recombinant Fab-fragment in bacteria was published 1988 
by Better et al. Even smaller fragments of antibodies having only the variable 
domains have been made. They have been connected by non-covalent forces 
between the varible domains, Fv (Skerra and Plückthun, 1988) or by covalent 
linkages such as a linker polypeptide chain in scFv (Bird et al.,1988, Huston et 
al., 1988) or by a disulphide bridge in dsFv (Glockshuber et al., 1990). Covalent 
linkages prevent the concentration-dependent dissociation of the Fv domains 
observed in low concentrations (Glockshuber et al., 1990). External factors such 
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as ionic strength, pH and the presence of the antigen can have an effect on the 
stability of the VH-VL-interaction (Arndt et al., 1998). Depending on the length 
of the linker between variable domains, single-chain antibodies can also form 
dimers and trimers, thus creating multivalent or bispecific binding (Holliger et 
al., 1993 Alfthan et al., 1995, Pei et al., 1997, Kortt et al., 1997, Arndt et al., 
1998). 
Fab-fragments and single chain antibodies are the most widely used antibody 
fragments in various in vitro applications. Reduced size has made it possible to 
express antibody fragments in various heterologous hosts (section 1.2.4) and to 
construct antibody libraries displayed in different ways (section 1.2.5). Small 
size is also advantageous in structure determination and in applications in which 
dense immobilisation of binding sites is preferred. Antibody fragments usually 
have the same intrinsic binding affinity as the monoclonal antibody (Bird et al., 
1988, Glockshuber et al., 1990, Hemminki et al. 1998a). However, especially in 
scFvs, if the variable chains are reoriented due to removal of the constant 
domains, some changes in affinity may occur (Huston et al., 1988, Wörn and 
Plückthun, 2001). 
1.2.4 Heterologous expression of antibody fragments 
Most often the antibody fragments have been produced in Escherichia coli and 
different expression strategies have been applied. Correctly folded antibody 
fragments can be produced to the periplasmic space between the inner and outer 
membranes of E. coli (Better et al., 1988, Skerra and Plückthun, 1988, Carter et 
al., 1992, Pack et al., 1993). The periplasmic space has reducing conditions and 
chaperones, leading to the formation of disulphide bridges and correct folding of 
the polypeptides. Production of antibody fragments to the periplasm may lead to 
leakage or partial lysis of the outer membrane and antibody fragments can then 
be collected from the culture supernatant. Single mutations to VH, (Forsberg et 
al., 1997) or optimised vector and growth conditions have been shown to 
prevent leakage and lysis of the bacterial cells (Pack et al., 1993, Horn et al., 
1996). If the signal sequence, which guides the synthesized polypeptide to the 
periplasm, is not included then the antibody fragments tend to accumulate in the 
cytoplasm and may form insoluble aggregates, inclusion bodies (Bird et al., 
1988, Proba et al., 1995, Sinacola and Robinson, 2002). Refolding of the 
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antibody fragments in vitro is then necessary and the success of this procedure is 
antibody-dependent (Sinacola and Robinson, 2002). For a review of expression 
of antibody fragments in E. coli see Plückthun, 1991. 
Using optimised expression vectors and high cell density-fermentation high 
production yields up to 1-3 g/L of the functional antibody fragment have been 
obtained. (Carter et al., 1992, Pack et al., 1993, Horn et al., 1996). The 
expression yields of soluble proteins can be improved by increasing the total 
expression level and also the folding yield, which is connected to the 
susceptibility of the antibody fragment to proteolytic degradation (deHaard et 
al., 1998). Co-expression of periplasmic chaperones have in some studies 
improved the functional expression of the antibody fragment (Bothmann and 
Plückthun, 1998, 2000, Mavrangelos et al., 2001). The choice of the expression 
vector, bacterial strain and conditions for cultivation, e.g. media composition 
and temperature, affect the final yield of soluble active antibody fragment. In 
addition to these extrinsic factors especially the amino acid sequence of the 
antibody but also the origin of the antibody and fragment type can have effect on 
the final yield. Despite identical production vectors and cultivation conditions up 
to 10-fold differences in production yields of different antibodies have been 
observed (Knappik and Plückthun, 1995). Even a single mutation can have a 
dramatic effect on the expression (Dueñas et al., 1995, Knappik and Plückthun, 
1995). Critical residues in e.g. turns on the surface or at the domain interface can 
have a great impact on expression (Knappik and Plückthun, 1995). The 
importance of the framework regions was shown in one study in which 
humanisation of an antibody improved the production 10100-fold compared to 
the parental murine antibody (Carter et al., 1992). In scFv antibodies the 
exposed hydrophobic patches may lead to aggregation and necessitate 
modification for improved yields of soluble antibody (Nieba et al., 1997). 
Studies to identify the critical positions in antibody frameworks for improved 
expression have been performed for various antibodies (Table 2). A systematic 
study with the human variable domains revealed differences in production levels 
of different germline family consensus domains and different combinations of 
the domains (Ewert et al., 2003a). Careful consideration is needed  if mutations 
are applied to a different framework, as the studies of deHaard et al. (1998) and 
Kipriyanov et al. (1997) have indicated. The change of glutamine to glutamate at 
position VH6 caused decrease in productivity of the class IIB antibody without 
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affecting the affinity, whereas the same mutation for several class IIA antibodies 
decreased their production levels and also induced loss in binding activity. 
Table 2. Some recent examples of antibody fragments engineered for improved 
production yields. S/M =both single and multiple mutations. 
Mutations scFv/Fab Origin Improvement Notes References
Single Fv human 10 -fold Engineered turns Knappik and Plückthun, 1995
Single scFv human 25 -fold VH84 Nieba et al ., 1997
Single scFv murine 30-fold VH6 Kipriyanov et al. , 1997
Multiple scFv murine 20 -fold Forsberg et al ., 1997
S/M scFv/Fab murine 0-9 -fold Mutagenesis study Hugo et al. , 2003
Multiple scFv human 2-4-fold Mutagenesis study Ewert et al. , 2003b  
In addition to bacteria other heterologous hosts such as yeast (Horwitz et al., 
1988, Shusta et al., 1998, Lange et al., 2001), insect cells (Laroche et al., 1991, 
Reavy et al., 2000), mammalian cells (Dorai et al., 1994), filamentous fungi 
(Nyyssönen et al., 1993) and various species of plant (jrecent review Churchill 
et al., 2002) have also been used to produce antibody fragments. A comparison 
of bacterial, yeast, insect and mammalian expression systems in the production 
of antibody fragments was presented by Verma et al. (1998). 
1.2.5 Antibody gene libraries and selection methods to obtain 
primary antibodies against haptens 
One important factor in the development of antibody-based applications is the 
efficiency of obtaining suitable antibodies. Antibody gene libraries provide an 
enormous potential to obtain new binding specificities for various antigens. Fab 
and scFv antibody phage display libraries have been constructed from 
immunised or non-immunised (naïve) sources. An antibody library can also be 
constructed synthetically or combinatorially. A wide variety of antibody libraries 
(Table 3) have been developed to produce new binding specificities but also to 
improve properties such as expression (Table 2), affinity, specificity and 
stability (for some examples see Tables 46). 
Antibody fragments have been displayed in vivo on viruses such as 
bacteriophages (McCafferty et al.,1990, Clackson et al., 1991, Marks et al., 
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1991, Hoogenboom et al., 1991) and baculoviruses (Mottershead et al., 2000), 
on bacteria (Fuchs et al., 1991, Georgiou et al., 1997 (review), Daugherty et al., 
1998, 2000) and on yeast ( Kieke et al., 1997, Boder and Wittrup, 1997, Boder et 
al., 2000, Feldhaus and Siegel, 2004 (review)). These microorganisms couple 
the phenotype to the genotype and take care of the amplification and the display 
of the antibody at the surface. However, the transformation efficiency of the 
microbes limits the diversity of the antibody library.  
Alternatively in in vitro display methods the genetic element is attached to the 
corresponding polypeptide, either non-covalently in ribosome display (Hanes 
and Plückthun, 1997, He and Taussig, 1997) or covalently in mRNA display 
(puromycin aided ribosome display) (Roberts and Szostak, 1997). Polymerase 
chain reaction (PCR)-based mutagenesis or DNA-shuffling (Stemmer, 1994) 
during selection rounds can be applied to improve the properties of the antibody. 
In vitro display methods are not restricted by the transfection efficiency and 
libraries having up to 1013 clones have been constructed (Hanes and Plückthun, 
1997, Roberts and Szostak, 1997). However, possibly due to technical 
difficulties the use of these in vitro display methods is at present not as 
widespread as in vivo display methods. For a recent review see Lipovsek and 
Plückthun, 2004.  
In the search for anti-hapten antibodies phage display followed by bacterial 
production has been a widely used combination and is therefore briefly 
described here. The first example of an antibody fragment (scFv) displayed on 
the surface of a filamentous phage was presented by McCafferty et al., (1990). 
The genes of the variable regions of an antibody were fused to pIII, one of the 
phage coat proteins. Fusion protein was displayed on the surface of the phage 
and the link between phenotype and genotype was formed. Soon the display of 
active Fab-fragments was also reported (Hoogenboom et al., 1991). The first 
antibody library (scFv) from immunised mice was constructed and used for 
selection of specific antibodies by Clackson et al., (1991). Antigen biased 
libraries from immunised sources have been constructed since then and used to 
obtain binders for immunogenic antigens such as hapten-protein conjugates 
(Clackson et al., 1991, Barbas et al.,1992, Burmester et al., 2001). Immunisation 
enriches the amount of antigen-specific B-lymphocytes and enhances the 
transcription of rearranged antibody genes, which facilitates the selection 
procedure. Libraries of immunised sources usually produce antibodies with 
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affinities corresponding to the secondary immune response. However, for 
selection of another antigen a new immunisation and library construction is 
usually needed. Other forms of preliminary enriched libraries are the patient-
specific antibody libraries which have been constructed to obtain human 
antibody fragments against disease-related antigens of e.g. cancers or allergies 
(Cai and Garen, 1995, Steinberger et al., 1996, Laukkanen et al., 2003).  
Marks et al., 1991 reported the construction of the first naïve antibody library 
from non-immunised source, making the immunisation procedure and the 
continual use of animals unnecessary. The affinities of antibodies obtained from 
naïve libraries are on average in the range of 106-107 M-1, (Hoogenboom, 1997) 
corresponding to the affinities usually obtained from primary immune response 
(Winter and Milstein, 1991). Some examples of non-immunised libraries are 
presented in Table 3. Naïve libraries are not restricted by the success of 
immunisation and they can be used to select antibodies for various antigens 
including non-immunogenic or toxic substances and evolutionarily conserved 
targets. Increasing the size of the libraries increases the probability of positive 
clones and the possibility to obtain high affinity antibodies with Ka around 109 
M-1 (Griffiths et al., 1994, Vaughan et al., 1996 de Haard et al., 1999). However, 
the antibodies selected from naïve libraries as well as from immunized libraries 
have variability in the whole amino acid sequence, leading to different properties 
in e.g. stability or expression levels. 
In addition to naïve and immunised libraries synthetic and combinatorial 
antibody libraries have also been constructed to obtain new specificities. 
Examples are presented in Table 3. Diversity of the antibody genes is not 
introduced by the immune system but is based on randomisation or design. 
Random strategies such as error-prone-PCR or mutator strains have been used to 
give diversity to the whole antibody fragment, and chain shuffling introduces 
new combinations of variable domains (reviewed by Hoogenboom 1997). 
In design-based approaches the synthetic or combinatorial diversity has been 
targeted to one or several CDRs in one or several frameworks (Table 3). The 
heavy chain CDR3 has been the frequently used target region for mutagenesis. 
Mutagenesis of the CDR-H3 alone has been applied to libraries having only one 
heavy chain (Barbas et al., 1992, Braunagel and Little 1997) or various heavy 
chains (Hoogenboom and Winter, 1992, Nissim et al., 1994, deKruif et al., 
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1995). Chowdhury and Pastan (1999) targeted randomisation to hot spots, DNA 
sequences that are naturally prone to hypermutations. Partial randomisation of a 
selected antibody may skew the variability towards the specificity of the original 
antibody and therefore is feasible for affinity maturation (examples in Table 4) 
or to decrease the cross-reactivity (examples in Table 5), although the protocol 
has also been used for the selection of totally new specificities (examples in 
Table 3). 
However, randomisation at the nucleotide level has the disadvantage of 
introducing bias to the sequence, stop codons and non-viable sequences that can 
cause problems in folding and display. In one synthetic combined HuCAL-
library the CDRs were randomised by trinucleotides having optimal codon usage 
for bacterial expression. This approach introduces extensive sequence and length 
variability to the selected region without producing unwanted additional stop 
codons and thus increases the functional diversity of the library. In the HuCAL-
library seven heavy and seven light frameworks representing the natural 
repertoire of human antibodies have been combined and the mutagenised CDRs 
are attached to these frameworks as prebuilt cassettes (Knappik et al., 2000). 
In another type of combinatorial library the vast repertoire of all six CDRs 
derived from the antibody genes of the B-lymphocytes were individually and 
simultaneously recombined to an optimal VH and VL frameworks (Jirholt et al., 
1998, Söderlind et al., 2000, Steinhauer et al., 2002, Azriel-Rosenfeld et al., 
2004). The advantages of this set-up are that all the CDRs are of natural origin 
and the non-functional loops can be avoided. The length, amino acid sequence 
and the combination of CDRs are varied at the same time. Antibodies have been 
obtained from the single framework library with typical binding site 
topographies of cavity, groove and planar binding surface for hapten, peptide 
and protein antigens, respectively (Söderlind et al., 2000). Libraries based on a 
single predetermined framework have the advantage that the scaffold can be 
selected or modified to have optimal properties, e.g. good stability and high 
production yield. 
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Table 3. Examples of antibody phage display libraries used for selection of new 
hapten binders. 
Source Size Format Reference
Naive hapten binders for
human 107 scFv phenyloxazolone Marks et al. , 1991
human 1010 Fab various haptens Griffiths et al ., 1994
human 1010 scFv fluorescein, DTPA Vaughan, 1996
human 108 scFv oestradiol Pope et al ., 1996
human 1010 Fab phenyloxazolone de Haard et al ., 1999
Synthetic Notes
human 107 Fab single framework, CDR-H3 random Barbas et al ., 1992
human 107 scFv 49 VH, CDR-H3 5 or 8 residues random Hoogenboom and Winter, 1992
human 108 Fab single framework, CDR-H3 and -L3 random Barbas et al ., 1993
human 108 scFv 49 VH, CDR-H3 random Nissim et al ., 1994
human 108 scFv 49 VH + 7 VL, CDR-H3 random deKruif et al. , 1995 
human 109 scFv single framework, CDR-H3 random Braunagel and Little, 1997
human 109 scFv/Fab 7 VH + 7 VL, CDR-H3 and -L3 random Knappik et al ., 2000
human 109 scFv single framework, recombined CDRs Söderlind et al ., 2000  
Most of the reported antibody libraries are in the scFv display format but some 
Fab display libraries have also been reported (Barbas et al., 1991, 1992, Kang et 
al., 1991, de Haard et al., 1999, Knappik et al., 2000). Fab fragments are 
monomeric both in phage display and as soluble proteins, which provides a 
benefit over single-chain antibodies. Due to the multimerisation tendency of 
some scFvs the resulting avidity effect may lead to enrichment of the low 
affinity binders and hampering the affinity ranking of the positive clones. 
The proportion of isolated positive clones depends on the library size, antigen, 
selection conditions and the number of selection rounds. The selection strategy 
influences the outcome: antibodies with different properties were isolated from 
the same library by two different selection methods (Lou et al., 2001). Antibody 
phage libraries and selection methods were reviewed by Hoogenboom, 1997, 
Hoogenboom et al., 1998, Bradbury et al., 2003 and Bradbury and Marks, 2004. 
The common selection strategies for anti-hapten antibodies displayed on a phage 
use hapten-protein conjugate immobilised to a solid support (McCafferty et al., 
1990, Barbas et al., 1991, Marks et al., 1991,) or biotinylated hapten in solution 
(Hawkins et al., 1992), and binders are caught by a hapten support or by a 
streptavidin-coated support, respectively. After washing, the eluted phages are 
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used for infection and the binders are subjected to subsequent rounds of 
enrichment. Especially the elution step affects the outcome. Elution with soluble 
antigen has been shown to increase the specificity (Hemminki et al., 1998a, 
Charlton et al., 2001), and the amount of eluting hapten may have an effect on 
the affinity of the binders selected (Schier et al., 1996, Hemminki et al., 1998b). 
For other properties than affinity and specificity different types of selection 
methods have been applied as discussed below. 
Screening of antibody libraries in an automated high-throughput format 
(Hallborn and Carlsson, 2002) can also be used to obtain anti-hapten antibodies. 
The conjugated haptens can be immobilised for ELISA type screens or the 
haptens can be modified with e.g. fluorescent label for detection purposes. 
Screening of an entire primary library would however be impractical and require 
a large amount of hapten. Therefore small or pre-enriched libraries are preferred 
for screening. Recently a new method, single-molecule-PCR-linked in vitro 
expression, has been used for rapid screening of mutant antibodies with 
improved affinity. 384-well plates were used in all steps and the total time 
period was less than 10 hours for amplification of the mutants, cell-free protein 
synthesis and screening of individual clones in ELISA-format (Rungpragayphan 
et al., 2004). The method is best suited for small libraries used e.g. to fine-tune 
the affinity or specificity. 
1.2.6 Improving the properties of antibody fragments 
In some cases fine-tuning of properties is required for better performance of the 
antibody fragments. Various libraries have been constructed and knowledge-
based approaches have been applied to improve the properties of an antibody 
obtained from hybridoma cell line or from the above-mentioned primary 
libraries (for examples see Tables 46). Here the improvements of the properties 
relevant for anti-hapten antibodies in in vitro applications are reviewed. The 
optimisation of other properties such as reduced immunogenicity and toxicity or 
construction of antibody fusion proteins for detection purposes is not included in 
this introduction. 
The antibody-antigen interaction is a combination of steric and electrostatic 
complementarity between the paratope of an antibody and the epitope of an 
antigen. Hydrophobic interactions, hydrogen bonds, salt links and van der Waals 
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interactions may all contribute to the binding. By increasing the number of 
specific interactions and the size of the buried surface area it is possible to 
improve the affinity. The binding properties of the antibodies have been 
improved by single mutations, random mutations to selected residues, random 
mutagenesis for the whole or some part of the fragment, CDR-walking, 
insertions in selected CDRs and chain shuffling (examples in Table 4). In 
general, the knowledge-based site-specific approaches to improve the affinity 
have not been widely used due to the lack of detailed high resolution structural 
data of antibodies and to the difficulty in predicting the possible conformational 
changes occurring during antigen binding (Dougan et al., 1998). Homology 
modelling has been used successfully to target single residues or areas for 
mutagenesis (Roberts et al., 1987, Ruff-Jamison and Glenney, 1993, Iba et al., 
1998, Hemminki et al., 1998a). At present mutagenesis, random or targeted, 
followed by selection for improved affinity continues to be a convenient method.  
Sometimes the association or the dissociation behaviour of the antibody has been 
the special target for affinity-tuning (Dueñas et al., 1996, Söderlind et al., 2001, 
Jirholt et al., 2001, Hugo et al., 2003). In many antibody applications the kinetic 
parameters of the binding are important. In diagnostic and immunoaffinity 
applications as well as in therapeutic applications and antibody chip 
technologies a high association rate is crucial. Katakura et al., (2004) developed 
a kinetic model to improve the isolation of such antibodies. On the other hand 
the dissociation rate constants are very important in applications such as 
continuous monitoring and affinity chromatography applications, which prefer a 
rapid dissociation (Hugo et al., 2003). Some examples of affinity engineering of 
hapten-binding antibodies are listed in Table 4. As high as femtomolar affinity 
has been achieved (Boder et al., 2000). 
Table 4. Examples of remarkable affinity improvements of anti-hapten 
antibodies. * 24 amino acid inserts to CDR-H2 
Target area Hapten Affinity Notes References
improvement
12 residues Phosphotyrosine 10-fold Ruff-Jamison and Glenney, 1993
5 residues Cortisol 8-fold Improved specificity Chames et al ., 1998
CDRs Testosterone 12-fold Hemminki et al ., 1998
CDR-H2 Estradiol 12-fold Improved specificity Lamminmäki et al ., 1999*
Whole fragment Fluorescein >1000-fold Boder et al ., 2000
Whole fragment Fluorescein 30-fold Jermutus et al ., 2001  
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Specificity requirements for the antibody fragment depend on the application. In 
general high specificity is preferred and some examples of antibody engineering 
to decrease cross-reactivity are listed in Table 5. Random mutagenesis to defined 
areas has been a successful approach for specificity optimisation. High 
specificity is important for diagnostic antibodies and especially in cases in which 
the cross-reacting compound may be present in samples at high concentrations. 
Determination of different steroid hormone levels in human sera samples is a 
good example of a high requirement of specificity of anti-hapten antibodies 
(Pope et al., 1996, Hemminki et al., 1998a, Lamminmäki et al., 1999). On the 
other hand in applications such as affinity chromatography and antibody-based 
solid-phase extraction the binding of related substances can sometimes be 
considered advantageous. Cross-reactivity for structurally similar compounds 
makes it possible to capture all of them simultaneously and to subject the 
enriched mixture to further identification and quantitation (Houben et al., 1999, 
Delaunay-Bertoncini and Hennion, 2004). 
Table 5. Examples of specificity engineering of anti-hapten antibodies. Antibody 
libraries aiming at new specificities are presented in Table 2. *17-α 
hydroxyprogesterone, ** many clones with different specificities. 
Target area Hapten Change in specificity References
Heavy chain Estradiol reduced cross-reactivity Saviranta et al ., 1998
CDRs Testosterone reduced cross-reactivity Hemminki et al. , 1998 ab 
3 CDR 17-OHP* broadened specificity Iba et al ., 1998
SDRs Digoxin altered specificities** Chen et al ., 1999
CDR-H2 Estradiol reduced cross-reactivity Lamminmäki et al ., 1999
3 CDR + random VH 11-deoxycortisol altered specificity Miyazaki et al ., 1999
5 or 10 residues Digoxin altered specificity Short et al ., 2001
Whole fragment Sulphonamides broadened specificity Korpimäki et al ., 2003  
Stability is an important requirement for all antibodies, independent of 
specificity. In vitro applications may require antibodies with a long half-life, 
high stability in organic solvents and resistance to surface denaturation and dry 
atmosphere. Natural antibody frameworks have very different stability properties 
(Ewert et al., 2003a). Single amino acids may have a great impact on stability 
(Honegger and Plückthun, 2001). Two aspects of stability engineering, structure-
based framework engineering and CDR-grafting to more stable frameworks, 
were recently studied by Ewert et al., 2004. CDR-grafting is a way introduce the 
valuable binding properties of CDRs to a superior framework. Targetted 
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mutations can be used to refine the stability of an antibody. Mutations affecting 
stability may influence e.g. the packing of the hydrophobic core, hydrogen 
bonding or charge interactions. The importance of the disulphide bridges for 
stability was indicated by several authors (Glockshuber et al., 1990, Proba et al., 
1997, 1998), although scFv with sufficient stability can tolerate the loss of both 
disulphide bridges (Wörn and Plückthun 1998b). High temperatures or 
denaturants have been used to introduce selection pressure for increased stability 
of antibody fragments (Proba et al., 1998, Jung et al., 1999). Examples of 
successful stability engineering are presented in Table 6. Different aspects of 
stability engineering of scFvs were reviewed by Wörn and Plückthun (2001). In 
addition to the protein engineering approach, chemical cross-linking by e.g. 
glutaraldehyde has been used to stabilise the antibody fragments (Glockshuber et 
al., 1990, Vuolanto et al., 2004). 
The stability of an antibody sometimes correlates with the expression yield (Jung 
and Plückthun, 1997, Jung et al., 1999, Ewert et al., 2003b) and even a single 
amino acid replacement can improve both stability and expression (Hugo et al., 
2003). The balance between the correct folding and aggregation may also depend 
on a single amino acid (Knappik and Plückthun 1995). The best correlations 
between stability and production level have been obtained with cytoplasmic 
expression, whereas the correlation of stability with periplasmic expression is less 
straightforward, e.g. mutations increasing the periplasmic expression of anti-
fluorescein scFv had no influence in stability (Nieba et al., 1997). 
Table 6. Examples of stability engineered recombinant antibody fragments. Loop 
(or CDR) grafting = 1-6 CDR loops of one antibody are transferred to a more 
optimal framework.  
Target area Origin Fragment Notes References
Loop grafting murine scFv also improved expression Jung and Plückthun, 1997
Single replacements murine scFv Wörn and Plückthun, 1998a
Single replacements humanised scFv also improved expression and affinity Jung et al ., 1999
Whole fragment human scFv Jermutus et al ., 2001
Six replacement human scFv also improved expression Ewert et al ., 2003b
Single replacement murine scFv/Fab L34, also improved expression Hugo et al ., 2003  
Targetted and knowledge-based engineering has been applied to improve the 
crystallisation properties of antibodies. Surface mutagenesis was applied to 
introduce a packing motif to the β-strand of variable domain in order to promote 
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their crystallisation propensity (Wingren et al., 2003). Immunoreactivity, 
expression and overall structures of the antibodies were maintained. Rational 
design of packing motifs promoting crystallization also opens new possibilities 
for anti-hapten antibody applications, see section 1.3.5. 
1.2.7 Specific features of anti-hapten antibodies 
Antibodies recognising small haptens typically have concave antigen binding 
sites compared to the flattened binding sites of antibodies against 
macromolecules such as proteins, although some exceptions do exist 
(MacCallum et al., 1996). By analysing 381 sequences of murine and human 
antibodies with known antigen specificities Vargas-Magrazo et al. (1995) 
concluded that different antigen types prefer different combinations of canonical 
structures of CDR loops. Some canonical structure classes are specific for 
certain antigens whereas others, called multispecific classes, are represented in 
antibodies recognizing different antigen types. Among the specific canonical 
classes a correlation between the length of the CDR-L1 and CDR-H2 loops and 
the antigen has been shown: e.g. antibodies against haptens prefer long L1 and 
H2 loops. In addition there is some correlation between the antigen type and the 
amino acid composition of CDRs. Certain residues are under or over
represented in hapten binders. (Collis et al., 2003). In anti-hapten antibodies 
most of the contacting residues are located close to the centre of the binding site, 
whereas larger antigens are also in contact with less central CDR residues 
(MacCallum et al., 1996). The knowledge of the special features of anti-hapten 
antibodies can be applied e.g. to the design of synthetic or combinatorial 
antibody libraries for anti-hapten binders. 
Due to the fact that low molecular weight compounds are not capable of elicting 
an immune response these compounds must be linked to a macromolecule via a 
linker before immunisation. Furthermore the current selection methods for 
antibody phage libraries require conjugated hapten. The linking of haptens to 
proteins or to e.g. biotin can be very problematic, requiring sophisticated 
chemistry. Due to the linking the anti-hapten antibodies may recognise the 
hapten and a part of the linker (the bridge effect) (Barbas et al., 1992, Tuomola 
et al., 2000, Kusharyoto et al., 2002, Monnet et al., 2002). In such cases the 
antibody may have significantly lower affinity for the hapten alone. In principle 
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the linking may also distort the structure of the hapten and the antibody therefore 
recognises the conjugated more strongly than the native form of the hapten. The 
composition of the linker and the conjugation site of the hapten have an impact 
on the binding affinity and specificity of the selected antibody. Site-directed 
mutagenesis to reduce binding to the linker moiety (Kusharyoto et al., 2002) or 
optimisation of the panning strategy, have been used to increase the specificity 
for the hapten moiety (Charlton et al., 2001, Kramer, 2002). Specific elution 
with soluble hapten increased the recovery of hapten-specific antibodies, in 
comparison to unspecific elution which produced binders against hapten 
conjugate (Barbas et al., 1992, Charlton et al., 2001). According to Kramer 
(2002) immunisation with a hapten conjugate produces non-redundant 
antibodies, making selection of anti-hapten antibodies difficult. In their approach 
the B-cells of immunised mice were enriched with hapten-coated magnetic 
beads before constructing the library. Using this approach 75% of the clones 
were specific binders after three cycles of panning. 
1.2.8 Site-specific immobilisation of recombinant antibody 
fragments for affinity chromatography 
In most applications a high density antibody immobilisation is preferred. The 
importance of the optimal method of immobilisation increases as the size of the 
antibody fragment decreases. The smaller the antibody fragment, the more 
crucial it is to have oriented and site-specific immobilisation. Immobilisation 
should be efficient and stable and occur in conditions compatible with the 
antibody fragment. Random immobilisation, such as in the case of methods 
using passive adsorption to a surface or covalent linkage between reactive 
groups of the immobilisation surface and the lysine residues of the antibody, 
usually causes decreased binding capacity (Spitznagel and Clark, 1993, Peluso et 
al., 2003). Immobilisation may take place directly via lysine residues on CDRs, 
or the antibody can become partially denatured due to multipoint attachment to 
the support. Random orientation of antibody fragments may cause steric 
hindrance of antigen binding. However, steric hindrance has less effect on the 
binding efficiency of low-molecular weight haptens than on the binding of larger 
protein antigens (Schramm and Paek, 1992, Spitznagel and Clark, 1993). 
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Denser packing of Fab-fragments and up to 10-fold improvements in antigen 
binding capacity were obtained by site-specific compared to random 
immobilisation (Peluso et al., 2003). Various strategies have been developed for 
site-specific and oriented immobilisation of recombinant antibody fragments. An 
antibody fragment can be captured in an oriented way on the surface by 
intermediate proteins such as Protein G or streptavidin (for biotinylated 
antibodies). However the demands for immobilisation in affinity 
chromatography differ from those of other antibody applications due to the 
elution step. Every component and linkage on the immobilisation must also be 
stable in the conditions used to release the bound molecule. Various non-
covalent immobilisation strategies have been reviewed by Burgess and 
Thompson (2002). 
For recombinant antibody fragments a widely used approach is genetically fused 
immobilisation tags. Introduction of a single cysteine to the carboxy terminus of 
an antibody fragment has been used for covalent immobilisation (Kipriyanov and 
Little, 1997). A slightly longer tag for both purification and immobilisation 
purposes, a histidine tag, provides a versatile approach. Since Hochuli et al., 1987 
reported that adjacent histidine residues can be used to immobilise a protein to the 
metal-affinity chromatography support, various histidine-containing peptides have 
been fused to recombinant antibodies (Skerra et al., 1991). A tag of six histidine 
residues is the most widely used. A number of histidines has varied between 2 and 
9. Efficient, over 90% immobilisation can be obtained by three or more histidines 
but the stability of the binding increases as a function of additional histidines 
(Hochuli et al., 1988). The binding strength and efficiency can also be adjusted by 
the choice of immobilised metal, because different metals have different binding 
strengths for a chelate (Cu > Ni > Co = Zn) (Arnold, 1991). For a recent review of 
immobilised metal affinity chromatography (IMAC) see Ueda et al., 2003. 
Kinetically stable immobilisation via histidine tags can be achieved by 
immobilisation to a cobalt support followed by oxidation (Hale, 1995). Oxidised 
metal affinity support is resistant e.g. to low pH, which broadens the usability of 
this immobilisation method. 
In addition to short peptides whole binding domains, such as cellulose- and 
chitin binding domains, have been fused to antibody fragments in order to 
immobilise fusion proteins directly from the crude bacterial lysate to 
inexpensive and environmentally friendly supports of cellulose and chitin, 
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respectively (Reinikainen et al., 1997, Linder et al., 1998, Blank et al., 2002, 
Azriel-Rosenfeld et al., 2004). For a review of different affinity fusion strategies 
for recombinant proteins see Nilsson et al. (1997). 
1.3 Applications of enantioselective antibodies 
1.3.1 Background 
Specific preparative fractionation of enantiomers is needed after chemical 
synthesis of a chiral compound. Although enantioselective synthesis has been 
under extensive development, at the early stages of compound development the 
separation approach still dominates over the asymmetric synthesis Maier et al. 
(2001). Setting up an asymmetric synthesis is time consuming and expensive. 
Enantiomers can be separated from each other by indirect or direct methods. 
Indirect methods include a derivatisation step with an enantiomerically pure 
compound, followed by separation by fractional crystallisation or by 
conventional chromatography. Later the derivatizing agent is removed and the 
enantiomer is purified. This method has been widely used in the pharmaceutical 
industry due the relatively easy scale-up. Direct methods in preparative scale 
such as chiral chromatography based on either chiral liquid- or solid-phase need 
no modifications to the enantiomer prior to the fractionation. Various organic 
chiral selectors (reviewed by Ward, 2000) and unspecific proteins have been 
used as chiral phases (reviewed by Millot 2003). According to Rouhi (2003), the 
interest in continuous chiral chromatography is growing. The tendency is to 
develop the specific chiral stationary phase for preparative applications, rather 
than more general or broad selectivity supports (Armstrong and Zhang, 2001). 
Pharmaceutical, forensic, biochemical and environmental analyses are 
performed for a wide variety of analytes from different matrices such as plasma, 
urine, tissue, saliva, hair, water, foods and soil. A common feature of all these 
analyses is that the sample matrices are complex, have potential interferences 
and the analytes are in low concentration. Tedious sample preparation with 
many steps is usually required. However, the use of several purification steps 
before analysis is not preferred because all additional clean-up steps introduce a 
risk of losses and decrease the reliability of the method. Sample preparation is 
one of the most critical steps for reliable results. Especially in the 
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pharmaceutical industry the trend is to develop single-step automated sample 
preparation methods in high-throughput format with on-line coupling to the 
separation and detection techniques (Koh et al., 2003 (review)). Different 
sample preparation approaches were described by Stevenson, 2000. In general, 
enantioselectivity is not included in the sample preparation but rather the 
following separation step. 
1.3.2 Antibody-based affinity chromatography 
Immunoaffinity chromatography (IAC) is a chromatographic method based on 
immobilised antibodies which bind the target compound from the sample matrix 
efficiently and in a specific manner. After subsequent removal of unwanted 
impurities from the support, the bound compound is eluted by disrupting the 
antibody-antigen complex using chaotropic agents, extreme pH, organic solvents 
or a different combination of these. A regeneration step is added to the protocol 
in the case of reusable immunoaffinity supports before the next round of 
separation. Immunoaffinity chromatography (IAC) has been used for specific 
purification of antigens (enzymes, receptors, peptides) and haptens (drugs, 
hormones, antibiotics, carbohydrates). For recent reviews see Hennion (1999), 
Muronetz and Korpela (2003). IAC is one of the most powerful methods for the 
purification and concentration of antigens from various sample matrices. An 
excellent review of different types of analytical applications of immunoaffinity 
chromatography was presented by Hage (1998), and the challenges facing 
separation of enantiomers was reviewed by (Maier et al., 2001). Various support 
materials for immunoaffinity applications were listed by Stevenson (2000). 
Most of the antibodies used hitherto in immunoaffinity columns have been 
polyclonal or monoclonal antibodies produced by immunisation. However, the use 
of recombinant antibody fragments would have many advantages over poly- and 
monoclonal antibodies, such as lower production costs and improved binding 
capacity due to the smaller size and oriented immobilisation via a tag. The 
possibilities to use antibody libraries in the search for new specificities, and antibody 
engineering to introduce tags and to adjust the properties, if needed, also increase the 
potential of immunoaffinity supports. An important parameter of immunoaffinity 
chromatography is the efficiency and specificity of the hapten binding, especially for 
low-concentration and high-volume samples. Modifying the selection method for 
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the antibody libraries would offer a possibility to obtain antibodies with suitable 
kinetic parameters (Section 1.2.6.). In immunoaffinity-based purification or in 
analytical applications, antibodies with fast association kinetics are preferred. Fast 
dissociation of the antigen or hapten in mild elution conditions is required for low 
volume recoveries or in the case of reusable affinity supports. (Ohlson et al., 1997, 
Burgess and Thompson, 2002). Reusability increases the economical feasibility of 
the immunoaffinity supports. Hofstetter et al. (2002) reported the continuous use of 
an immunoaffinity column for over 1000 cycles of purification of a hapten in 11 
months, without significant change in column performance. Reusability of an 
antibody support has been improved by crosslinking immobilised antibody 
fragments with glutaraldehyde (Vuolanto et al., 2004). 
Enantioselective antibodies have been used to fractionate chiral synthesis 
products (Mertens et al., 1982, Knox and Galfre, 1986) and other mixtures of  
enantiomers (Hofstetter et al., 1998, 2002) hitherto in a relatively small scale, 
probably due to the use of poly- and monoclonal antibodies. Enantiomers from 
biological samples such as sera, plasma and urine have been extracted by 
specific antibody supports for analytical purposes. Examples of enantioselective 
antibodies both in preparative and analytical applications have been collected 
into Table 7. Other applications for enantioselective antibody fragments are 
presented in section 1.3.5. 
Table 7. Examples of enantioselective antibodies in immunoaffinity applications. 
Enantiomers Sample matrix Antibody origin Reference
Abscisid acid Buffer  Antisera Mertens et al ., 1982
Abscisid acid Buffer  Monoclonal Knox and Galfre, 1986
Loxoprofen metabolites Plasma  Antisera Takasaki and Tanaka, 1992
Amino acids Buffer  Monoclonal Hofstetter et al ., 1998, 2002
Bufuralol and metabolites Plasma  Antisera Ikegawa et al ., 1998
Warfarin Serum  Polyclonal Clarke et al ., 2001
Ibuprofen-modified peptide Buffer  Polyclonal Ikegawa et al ., 2001
Amphetamine Urine  Monoclonal Lua and Chou, 2002  
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1.3.3 Antibody-based solid-phase extraction as a sample 
preparation method 
Solid-phase extraction (SPE) has become a popular method for sample 
preparation, and the development of new formats and sorbents has been rapid. 
Solid-phase extraction can be used to simultaneously isolate, concentrate, purify 
and change the medium of the analyte.  Antibody-based solid-phase extraction 
methods follow the same principles as immunoaffinity chromatography except 
having much less theoretical plates due to the shorter length of the column. The 
difference between immunoaffinity chromatography and antibody-based solid-
phase extraction is that the former is a separation method coupled to a detection 
system whereas the latter is an extraction method coupled to separation and 
detection systems either on- or off-line. Most commonly the SPE is combined 
with the chromatographic and electrophoretic separation methods. SPE-HPLC 
(high performance liquid chromatography)-combinations are routinely used due 
to the relatively easy connection of these two techniques. The coupling with 
capillary electrophoresis (CE) is less widely used because of the technical 
complexity, although some examples already exist even for immunosorbents 
(Guzman, 2000). SPE-CE combinations have potential for microscale analysis 
due to their low sample and reagent consumption, great resolution and speed. 
Different sorbent types can be used in SPE. Non-specific sorbents include 
inorganic oxides (silica gel, alumina, diatomaceous earth), chemically bonded 
silicas (C8/C18), porous polymers and carbon. Compound- and class-specific 
sorbents are based on ion exhange, restricted access or specific affinity of 
proteins or molecularly imprinted polymers. Different sorbent types were 
compared and examples were presented by Poole, 2003. A common feature of 
non-specific sorbents is their lack of specificity; they are unable to distinguish 
between enantiomers and they co-extract interfering molecules from the sample 
matrix (Maurer et al., 2000, Rolcik et al., 2002, Hennion  and Pichon, 2003), 
which can become a problem especially when the analyte is at a trace level and 
the interfering compounds are present at higher concentrations. Co-eluted 
interferences may cause problems and even suppress the formation of analyte 
ions in the electrospray process of the MS-detection. Specific antibody-based 
extraction prior to MS-detection has been shown to improve the sensitivity of 
the analysis considerably by increasing the signal-to-noise ratio (Ferguson et al., 
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2001, Rolcik et al., 2002). Figure 5 illustrates clearly the importance of specific 
extraction of the analyte before MS-detection. 
Figure 5. Comparison of LC-MS analyses. a) melatonin- spiked human plasma 
extracted by C18-SPE (the arrow indicates the melatonin). b) melatonin-spiked 
plasma extracted by a specific immunosorbent (Modified from Rolcik et al., 2002). 
Immuno-SPE is an antibody-based solid-phase extraction providing an 
interaction with high affinity and specificity for the analyte. The properties of 
the antibodies are the key determinants for successful extraction due to a strong 
correlation between recovery of the analyte and the affinity of the antibody 
(Hennion and Pichon, 2003). Immuno-SPE has potential to solve some of the 
problems of the unspecific SPE. The breakthrough volumes for immunosorbents 
are higher than for non-specific sorbents which makes the binding of low-
concentration analytes from high volumes more efficient. Immunosorbents can 
also be enantioselective and therefore provide an additional advantage. For 
examples of different immunosorbents in SPE see the recent review by 
Delaunay-Bertoncini and Hennion, 2004. 
Most of the present immunoaffinity sorbents are based on poly- or monoclonal 
antibodies. Few examples of antibody fragments, digested from monoclonals, 
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have emerged (Phillips and Krum, 1998, Guzman, 2000, Clarke et al., 2000). 
Hitherto the potential of antibody libraries as a source of specific binders has not 
been utilised. According to Delaunay-Bertoncini and Hennion (2004) the use of 
antibody fragments is one of the future directions in the development of 
analytical systems, the others being miniaturization of analytical microsystems 
and chip technology. 
In classical immunoassays cross-reactivity is typically a problem, whereas in 
solid-phase extraction it may be even desirable. Cross-reactivity is preferred if a 
class of compounds, such as closely related pesticides or a drug and its 
metabolites, are to be extracted and the following separation and detection steps 
are to be used for the identification. The cross-reactivity of an antibody must be 
determined experimentally in the format of intended use. For example, although 
only a little binding of related compounds (phenylureas) was observed in ELISA 
(Enzyme-linked immunosorbent assay) -assay of isoproturon and chlortoluron, a 
strong retention of these phenylureas was observed in the column format 
(Stevenson, 2000). Most examples reported as cross-reacting immunosorbents 
are made of using polyclonal antibodies and a few of immunosorbents based on 
actually cross-reacting or group-specific monoclonal antibodies have been 
reported (Houben et al., 1999, Delaunay et al., 2003). Mimicking in a controlled 
way the polyclonal approach the immunosorbents simultaneously binding 
different analytes could be created by immobilising more than one specific 
antibodies to the SPE support when the analytical method is used to identify the 
eluted compounds. This possibility greatly increases the versatility of the 
immunoaffinity sorbents. 
On-line connections in general require compatibility between the extraction and 
the separation, e.g. the chemical composition of the buffers and the pressure 
resistence of the sorbents should be compatible. On-line connection is 
automatable and minimal sample handling and solvent consumption is 
necessary. On the other hand the off-line connection does not limit the properties 
of the buffer or the sorbent because the eluent of the first step can be evaporated 
to dryness and later reconstituted to the conditions preferred by the later 
separation or analysis. With an off-line method an enrichment factor of over 100 
has been obtained for one analyte (Ferguson et al., 2001). 
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Most frequently the final analysis of the compounds has been performed by 
measuring the UV-absorbance or fluorescence. Mass spectrometric (MS) 
detection has also been used after the SPE and the separation technique (Maurer 
et al., 2000, Wu et al., 2001, Ferguson et al., 2001, Rolcik et al., 2002).  Mass 
spectrometric detection is especially useful after a class-selective extraction if 
the components of the eluent are identified in addition to their quantitation (Wu 
et al., 2001). The advantage of the direct coupling of SPE and MS is the 
increased speed when the separation step between the extraction and detection 
techniques is excluded. 
Extraction formats differ depending on the sample matrix. Single columns of 
unspecific supports have been used for environmental analysis, whereas the 
analysis of drugs, metabolites and endogenous compounds has moved from 
small columns towards the automated 96-well filtered microtiter plates 
(Souppart et al., 2001, Matthews et al., 2002, Bakhtiar et al., 2002, Shou et al., 
2002, Pommier et al., 2003, Svennberg et al., 2003, Yang et al., 2003, Kim et 
al., 2004) and also recently to 384-well filtered microtiter plates (Rule et al., 
2001) Automated solid-phase extraction is gaining popularity, especially in 
replicate analysis. Automation saves operation time and improves precision and 
safety if hazardous samples are used. Contamination between close wells may 
however limit the use of the plates at the moment (Majors, 2001). These aspects 
and future prospects of automatisation of SPE were more widely reviewed by 
Rossi and Zhang (2000). Hitherto, antibody-based solid-phase extractions have 
been performed only in the column format, although the column size has been 
decreasing down to microcolumns. 
1.3.4 Enantioselective antibody crystals 
Immunoaffinity columns separate the enantiomers efficiently and the continuous 
use of the affinity supports is possible (Ikegawa et al., 1998, Houben et al., 
1999, Rejeb et al., 2001). Compared to non-specific chiral columns in which the 
separation is based on partition leading to large elution volumes, the bound 
compounds from immunoaffinity columns are eluted in higher concentration. 
Decreased solvent consumption is one of the goals in the chemical and 
pharmaceutical industry. Elution volume depends on the efficiency of the eluent 
but the volume of the columns also plays a significant role. Typically 8095% of 
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the column volume of the immunosorbents is due to the volume of the support 
(Vuolanto et al., 2003, 2004). Crystallisation of antibody fragments is the most 
dense way of packing of antibodies and cross-linking the antibodies in crystals 
makes this type of antibody supports very stable. Separation of the enantiomers 
of a drug candidate was performed with crystallised and cross-linked 
enantioselective Fab-fragments and the miniaturised column was reusable 
(Vuolanto et al., 2003). Cross-linked antibody crystals were insoluble even in 
100% methanol (Vuolanto et al., 2003). In addition to improved solvent stability 
increases in thermostability and protease resistence of the cross-linked protein 
crystals have also been reported (Govardhan, 1999, Vuolanto et al., 2004). 
1.3.5 Examples of in vitro detection of enantiomers 
In principle all antibody-based diagnostic methods designed for low molecular 
weight haptens can also be applied to enantiomer analytics. The 
enantiospecificity of the detection methods originates from the properties of the 
antibody fragments used. Natural low molecular weight chiral compounds 
analysed from biological matrices generally have only one enantiomer due to 
their asymmetric synthesis by the enzymes in vivo. Therefore enantiospecific 
detection has not played a significant role in the diagnostics of endogenous 
compounds.  However, when the presence of exogenous compounds is to be 
determined, enantioselectivity may become an important factor. Drug abuse is 
an illustrative example. Amphetamine and its derivative metamphetamine are 
both chiral compounds and are widely used as illegal drugs. However they are 
also in vivo metabolites of some legal drugs and a definite knowledge of 
amphetamine metabolism and enantiomeric disposition is needed. (Peters et al., 
2002, Lua and Chou, 2002). Enantiomeric drug and metabolite analysis assists 
the investigation process when the source of these compounds must be 
confirmed in forensic analysis before legal actions. Recently an enantioselective 
immunoaffinity chromatography was developed to determine metamphetamine 
from urine samples of drug addicts (Lua and Chou, 2002). 
Enantioselective antibodies have also provided a tool to investigate rare in vivo 
effects of a drug. Ito et al., (2004) used enantioselective polyclonal antibodies in 
enzyme immunoassay and immunoblotting in order to study the enantioselective 
in vivo conjugation of ibuprofen to the proteins. They were able to identify 
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cellular target proteins modified by the reactive metabolite of ibuprofen. 
Enantioselective antibodies were used to examine the mechanism of ibuprofen-
induced cytotoxity. In general, a corresponding antibody-based approach could 
be used to study more widely the importance of protein modifications of both 
chiral and non-chiral drugs or other exogenous compounds. 
In addition to the various medical applications, antibodies can also be used in 
environmental applications (Van Emon et al., 1998, Kramer and Hock, 2003). 
Immunoextraction has already been coupled to ELISA or enzyme assays in order 
to increase the sensitivity in environmental monitoring of cyanobacterial toxins 
(Rivasseau and Hennion,1999). Immunoaffinity purification of soil extracts prior 
to ELISA increased the sensitivity of a herbicide assay 100-fold (Sheedy and 
Hall 2001). Enantioselective antibodies have the potential to solve specific 
analytical tasks. For example polychlorinated biphenyls (PCBs) are stable chiral 
pollutants that bioaccumulate and cause potential health hazards in aquatic 
ecosystems. Some macrozooplanktons are able to metabolise these pollutants 
stereoselectively (Wong et al., 2004). It is likely that the biotransformation is the 
major long-term removal process for these compounds. Enzymes perform 
enantioselective reactions and the possible involvement of biodegradation in the 
destruction of PCBs can be concluded from the enantiomeric excess of the chiral 
pollutants. The chiral analysis is a very important diagnostic tool to study these 
biodegradation processes and also to investigate the stereoselective biological 
and toxicological effects of the enantiomers of pollutants in different species in 
food webs. Many pesticides and herbicides are also chiral compounds, and the 
activity often resides preferentially in one of the enantiomers. The other 
enantiomer may be toxic to non-target organisms (Wang et al., 2004) and the 
undesirable environmental loading may be due to the applied racemate. 
Examples of antibodies used in environmental monitoring were reviewed  by 
Van Emon et al., 1998. 
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1.4 Aims of the present study 
The general aim of this work was to study and develop antibody-based methods 
for separation and analysis of enantiomers. A drug candidate was used as a 
model compound. The specific objectives were: 
1. To study the applicability of immobilised antibody fragments in 
repeated separations of enantiomers in affinity columns. 
2. To investigate the possibility to prepare enantioselective antibody-based 
nanomembranes in order to enhance the versatility of the method. 
3. To determine the affinity, specificity and stability requirements for 
antibodies in applications developed in this thesis. 
4. To develop in a high-throughput format a solid-phase extraction method 
based on immobilised antibody fragments. 
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2. Materials and methods 
2.1 The methods used in the original papers of this 
thesis 
Method Used in 
Linker synthesis for the hapten I
Immunisation and screening of monoclonal antibodies I
Cloning of Fab-fragments, ENA5His and ENA11His I
Construction of a homology model of ENA5His III
Design of mutations to ENA5His III
Site-specific mutagenesis of ENA5His III
Production and purification of the Fab-fragments I, III
ELISA, SDS-PAGE, Immunoblotting I, III
Immobilisation of the Fab-fragments
Copper -IMAC I, III
Cobalt - IMAC IV
Aldehyde derivatised silica II
Affinity measurements I, III
Immunoaffinity columns I, III
Continuous enantioseparation I, III
Solid-phase extraction IV
HPLC-analysis of the enantiomers I, III, IV
MS-analysis of the enantiomers IV
Derivatisation of silica nanotubes II
Immobilisation of the Fab-fragments into the nanotubes II
Facilitated diffusion in enantioseparation II
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2.2 Fabrication of alumina membranes 
Alumina membrane was prepared by anodisation of 0.1 mm thick (Alfa Aesar) 
aluminium foil. The foil was first polished manually with 94% ethanol followed 
by electropolishing in a mixture of 80% H3PO4, 10% H2SO4 and CrO3 (20g/l) for 
1015 min (15 V, 70 °C). Two-step anodisation was performed in a bucket 
containing 5% oxalic acid/water (0 °C) at a constant voltage of 20100 V for 24 
hours. Stainless steel was used as a cathode. 
The formed alumina was removed in a aqueous solution of 0.2 M CrO3, 0.4 M 
H3PO4 at 6070 °C for one hour. The anodisation protocol was then repeated in 
the same conditions, but the anodisation time was adjusted to obtain the desired 
thickness of the growing membrane. The voltage determined the pore size of the 
growing membrane. After growing the alumina membrane the residual 
aluminium layer from the other side of the membrane was removed in saturated 
HgCl2 solution. Sonication for 15 min was used to open pore ends. Openess and 
even size of the pores was checked by atomic force microscopy (AFM). Sol-gel 
synthesis, protein immobilisation and diffusion experiments are described in 
Appendix II. 
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3. Results and discussion 
The drug candidate 4-[3-(4-fluorophenyl)-2-hydroxy-1-[1,2,4]triazol-1-yl-propyl]-
benzonitrile (Figure 6 a), called hereafter diarylalkyltriazole, has two chiral centres 
(Södervall and Mutikainen 2002). Therefore its chemical synthesis produces four 
different stereoisomers (Figure 6 b). The diastereomers can easily be fractionated 
from this mixture but the enantiomers are difficult to separate from each other by 
chemical or physical means. The spatial arrangement of the substituents of 
diarylalkyltriazole differs between enantiomers as illustrated in Figure 7. 
a. b. 
Figure 6. a) The structure of 4-[3-(4-fluorophenyl)-2-hydroxy-1-[1,2,4]triazol-1-
yl-propyl]benzonitrile (diarylalkyltriazole). b) Stereoisomers of diarylalkyltriazole 
and their stereochemical relations. 
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Figure 7. The superimposed conformations of the SS- (blue) and the RR-(red) 
enantiomers of diarylalkyltriazole. Chiral centres are marked with an asterix. 
(Modelled and figure provided by Nana Munck, VTT Biotechnology). 
In this work, antibody-based methods for purification and analysis of racemic 
compounds were developed using diarylalkyltriazole, an inhibitor of the 
aromatase enzyme, as a model system. Efficient separation of the enantiomers is 
important for both the preparative fractionation of the racemic mixture and the 
specific analysis of the drug enantiomers. Different stereoisomers were named  
a-, b-, c-, and d-enantiomers according to their retention order from chiral 
ovomucoid column. The d-enantiomer was the most interesting enantiomer for 
drug development and was considered as the main target of the method 
development. Originally the configuration of the d-enantiomer was determined 
to be S,S. However, it was later found to be either R,S or S,R (Södervall and 
Mutikainen, 2002). The absolute configuration of the d-enantiomer has not yet 
been solved. However, for the experimental part of these method development 
studies the absolute configuration is of little importance and therefore the name 
d-enantiomer (and a-, b-, c-enantiomer for the others) is used throughout this 
thesis in order to avoid confusion. 
3.1 Enantioselective Fab-fragments: PCR-cloning, 
production and purification (I and III) 
Immunisation was used to obtain monoclonal antibodies, although at present a 
more convenient way would be selection from antibody libraries. A three-carbon 
linker was coupled to the racemic mixture containing enantiomers a and d 
(Appendix I, Figure 1) and this derivative was linked to the keyhole limpet 
hemocyanin for immunisation. Four monoclonal antibodies were obtained and 
screened by ELISA with racemate-BSA (Bovine serum albumin) conjugate 
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immobilised on microtiter plates (Appendix I). Two of them, named ENA5His 
and ENA11His, were cloned as Fab-fragments. A tag of six histidine residues 
was genetically introduced to the end of the light chains for purification and 
immobilisation purposes. A graphical presentation of the Fab-fragment with the 
hapten is shown in Figure 8. Modifications to the Fab-fragments made in this 
study are marked with a label. 
These two clones have no apparent sequence similarity at the CDRs. Their CDR-
loops vary both in length and in amino acid composition. The overall identities 
are 36% and 53% for the variable regions of heavy and light chain, respectively. 
Due to the low binding capacity of ENA11His and the too high affinity of the 
ENA5His to be used in continuous enantioseparation (described later in detail), a 
series of affinity mutants of ENA5His was designed to fine tune the affinity as 
described later in section 3.3. An oligonucleotide-based mutagenesis protocol 
was applied to introduce the mutations (Appendix III). The double mutant was 
cloned later by combining the most promising mutants of the heavy and light 
chain (Appendix III). 
Figure 8. A graphical presentation of the Fab-fragment. Hapten is inserted to 
the binding site composed of six hypervariable loops (gray). Framework regions 
of the variable domains and the VH1 and VL domains are in black. A six-histidine 
tag was cloned to the carboxy terminal end of the light chain for immobilisation 
purposes. Mutants were made in order to obtain an affinity more suitable for the 
applications. More detailed pictures of the mutations are presented in Figure 9. 
SIX HISTIDINE TAG 
FOR IMMOBILISATION
AFFINITY MUTANTS
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The production vector used for all constructions contained the tac promoter, 
which is controlled by the lacIq repressor. The pelB signal sequence of pectate 
lyase of Erwinia carotovora was linked to both the heavy and the light chains to 
promote secretion. (Alfthan et al., 1993) 
All Fab-fragments were produced in Escherichia coli bacteria (RV308 strain, 
ATCC 31608) using the high cell density cultivation method of Pack et al., 1993 
(Appendix I). Production levels of different constructions varied from 20 to 150 
mg purified Fab/ one litre of culture supernatant, determined by measuring the 
absorbance at 280 nm. The production yields are presented as purified protein 
because this final yield is the most relevant for the applications. Highest yields 
(80150 mg/L) were obtained for the parental Fab-fragments. Cell lysis occurred 
during the cultivations, leading to the extensive release of the periplasmic and 
cytoplasmic fractions to the medium. Production levels of the Fab-fragments 
were reasonably high, although not nearly as high as has been reported by Carter 
et al., 1992 (humanised Fab, 12 g/L, periplasm, ELISA-determination). Repeat 
cultivations were performed only with the parental Fabs and the mutant 
Tyr96Val. Due to the lack of replicate cultivations it is difficult to draw any 
conclusions about the effect of different mutations on the production levels.  
Purifications of Fab-fragments were performed with a two-step procedure. Metal 
affinity chromatography was followed by ProteinG affinity chromatography. No 
traces of other proteins were seen in SDS-PAGE analysis after purification. 
However, 1020% of the Fab-fragments, depending on the clone, had no 
interchain disulphide bridge and separate chains were observed in the non-
reducing conditions of SDS-PAGE (data not shown). The effect of the lack of 
the disulphide bridge on the applications is discussed in section 3.5.1 
3.2 Immobilisation of the Fab-fragments (I, II, III and IV) 
Recombinant antibody fragments can be immobilised either site-specifically or 
randomly, either covalently or non-covalently as briefly reviewed in the 
Introduction (Section 1.2.7). In most antibody applications there is a need for 
stable and oriented immobilisation. All the separation methods for enantiomers 
developed in this work employed immobilised antibody fragments, and the 
immobilisation strategy depended on the application. Common to the 
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immobilisation strategies used in this study is the required stability in relatively 
high concentrations of organic solvents or at low pH. The widely used 
immobilisation protocol via a six-histidine tag to the copper-loaded metal 
affinity support was used in the preparative fractionation studies of the racemate 
of the a- and d-enantiomers (Appendices I and III). Repeatedly over 95% of the 
Fab-fragments in PBS (phosphate buffered saline) were immobilised to the 
support. Immobilisation was stable over 20 cycles of continuous 
enantioseparation when 40% methanol-PBS was used as eluent. No light chain 
was observed in dried and reconstituted eluents analysed by immunoblotting 
with anti-kappa chain detection. However, after the first cycle of solvent elution 
the maximum capacity of the immunoaffinity support decreased (see section 
3.5.1), probably due to the dissociation of the heavy chain not connected via a 
covalent disulphide bridge to the immobilised light chain. A histidine tag could 
also be cloned to the carboxy terminal end of the heavy chain in order to 
improve the stability of the antibody support. No reduction in binding capacity 
of the antibody support was observed after six months of storage in PBS-0.02% 
sodium-azide at + 4 °C. 
In analytical applications, in which the aim was to use serum samples and 
eluents compatible with MS-analysis, another immobilisation strategy was 
needed. The high concentration of methanol required to release the bound 
analyte is not applicable directly to MS. The common approach to elute haptens 
from antibodies is to use low pH, which however also releases the Fab-fragment 
from the copper-IMAC support. Direct MS-analysis of a mixture containing a 
high amount of Fab-fragment as an impurity is not possible. Stable 
immobilisation during the low pH elution was required to prevent leakage of the 
bound Fab-fragments. Therefore the protocol of Hale (1995) was used to 
immobilise the Fab-fragments to the cobalt-iminodiacetic acid (IDA)-Sepharose 
support (Appendix IV). After immobilisation of the Fab-fragment and 
subsequent washes the support was subjected to mild oxidation with 0.03% H2O2  
in order to stabilize the linkage. Imidazole and EDTA washes were used to 
remove any unoxidized, labile attached antibodies and cobalt before 
equilibrating to the PBS buffer. Immunoblot analysis showed no leakage of 
antibodies from oxidised support in acidic elution conditions. 
Histidine tag  copper-IDA interaction was also tested in the immobilisation of 
antibody fragments to the functionalised nanotubes on the membrane but without 
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success, probably due to the multistep chemical activation of the nanotube needed 
for copper-IDA-coating. Therefore a method based on the linkage between lysine 
residues of the ENA11His and trimethoxysilylpropylaldehyde in the nanotubes 
was developed (Appendix II). ENA11His has lysine residues in the CDRs and it is 
probable that some of the randomly immobilised antibody fragments are attached 
to the tubes via the lysine residue in the enantiomer binding region. However, 
sufficient antibodies were immobilised in a suitable orientation, making the 
antibody-assisted diffusion of the enantiomer through the pores of the alumina 
membrane possible. The amount of functional antibodies inside the nanotubes of 
the membrane probably contributed to the efficiency of the facilitated diffusion of 
the hapten through the membrane. The amount of functional antibody fragments 
inside the nanotubes is however difficult to determine. 
Additional cysteines at the carboxy-terminus of the light chain of ENA5His and 
various cellulose-binding domain (CBD) fusions were also studied for covalent 
and non-covalent immobilisation of ENA5 Fab-fragments, respectively. 
Additional cysteines, depending their location, resulted in dimerisation or 
interfered with the disulphide-bridge formation of the Fab-fragment (data not 
shown). CBD-fusions suffered from low production levels and linker cleavage 
between the Fab and CBD during cultivation (data not shown). 
3.3 Building the homology model of the ENA5His (III) 
Results obtained from the affinity chromatography studies (presented in more 
detail in section 3.5) showed that the reusability of the column was dependent on 
the affinity of the immobilised antibody. The affinity of the ENA5His was too 
high for the repeated use of the antibody column because the conditions needed 
for efficient elution of the bound enantiomer led to partial denaturation of the 
antibody. On the other hand ENA11His had suitable affinity for repeated use but 
the capacity of binding was much lower than theoretically expected. Therefore a 
series of affinity mutants of ENA5His with lower affinity was designed. 
The aim was to reduce the too high binding affinity of ENA5His for the d-
enantiomer but to retain its specificity of recognition between the a- and d-
enantiomers. Two models, based on homologous antibody structures, were built 
for ENA5His as described in Appendix III. The amino acids most likely to have 
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contacts with the mutual part of the enantiomers were identified and five of them 
were chosen for the mutagenesis. 
Two models were made, due to the general difficulties in modelling of the 
CDR3 loop of the heavy chain having large conformational variation. The 
framework regions were the same in both models but the template structures for 
CDRs varied. Two and three mutations were designed on the basis of the models 
1 and 2, respectively (Figure 9). Their location at the sequence of ENA5His is 
shown in Figure 1 in Appendix III. The choice of the template structures for 
CDRs of the model 1 was made on the basis of the canonical class and maximal 
identity of the sequence. In the model 2 additional attention was paid to the 
structural similarity of the haptens of the template structures with respect to 
diarylalkyltriazole. Only the CDR2 loop of the light chain is common for both 
models (Table I, Appendix III). The location of the hapten is deeper in the 
binding pocket in model 2. All mutations (Trp33Ala, Thr97Gln and Tyr96Val) 
based on this second model reduced the affinity of the parental ENA5His 
antibody. 
a. b. 
Figure 9. The hapten binding sites of models 1 (9 a) and 2 (9 b). Mutated 
residues are indicated by the side chains. (Modelled and figure provided by 
Nana Munck, VTT Biotechnology) 
Aromatic residues, especially tyrosines, are in general common residues at the 
binding sites of antibodies (Collis et al., 2003). Tyrosine can participate in both 
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hydrophobic and hydrophilic interactions. ENA5His has 10 tyrosines and 3 
tryptophans and some of them showed stacking interactions with the buried part 
of the hapten in the molecular dynamics simulation. Two tyrosines and two 
tryptophans at the binding pocket were mutated in this study. Tyr94 and Tyr96 
were mutated to leucine and valine, respectively, causing loss of the aromatic 
ring and a possible hydrogen bond. Mutation Tyr94Leu showed a slight increase 
in affinity whereas the change in the other tyrosine caused up to 10-fold decrease 
in affinity. An exact explanation for the improved affinity of Tyr94Leu is 
difficult to obtain from the model. On the other hand, Tyr96 of the light chain is 
known from previous studies often to interact with antigen (MacCallum et al., 
1996, Chen et al., 1999 (Pro96) Jirholt et al., 2001, Kusharyoto et al., 2002). 
The two tryptophans of the heavy CDR-1 and CDR-3 were mutated to alanine 
and leucine, respectively. Trp33 has been shown to be an important residue for 
the binding (MacCallum et al., 1996, Chen et al., 1999, Jirholt et al.,  2001, 
Kusharyoto et al., 2002, Kobayashi et al.,  1999). In ENA5His the substitution 
of the bulky aromatic side chain to a small methyl group of alanine decreased 
the affinity ca 5-fold. Trp100J, located near the surface, was subjected to more 
conservative change to leucine, resulting nevertheless in a 6-fold decrease in 
affinity. In addition to possible deletion of a direct contact to the hapten, the 
reduction of the side chain volume may induce differences in positioning of 
close residues. The fifth mutation, Thr97Gln, was designed to introduce a drastic 
effect with the intention of creating a control to verify the models. The 
substitution of threonine with glutamine side chain caused almost 10-fold 
decrease in affinity. 
In order to understand in detail the specific effects of each mutant on the binding 
of the hapten the high resolution structures of the antibody with and without 
hapten are needed. Homology models have been used to design mutations (Ruff-
Jamison and Glenney, 1993, Chames et al., 1998), but more generally they 
provide a tool to target the mutagenesis study to the important residues or area at 
the binding site. Both affinity and specificity of anti-hapten antibodies have been 
adjusted successfully on the basis of homology models (Ruff-Jamison and 
Glenney, 1993, Iba et al., 1998, Hemminki et al., 1998a, Kusharyoto et al., 
2002). The chemical properties in the binding site of an antibody are much more 
complex than the sum of the properties of the amino acids forming the site. The 
characteristics of individual residues can however be used as a starting point to 
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understand the difference caused by mutation. The mutated amino acid may 
have direct contact with the hapten or it may have interactions with the antibody 
and thus indirectly have an impact on recognition. In some cases the binding of 
the hapten has been shown to induce conformational changes in antibody 
structure (Bhat et al., 1990, Stanfield et al., 1993, Arevalo et al., 1993, 
Wedemayer et al., 1997, Valjakka et al., 2002,) and these changes are very 
difficult to predict with any current computational methods. 
3.4 Binding properties of the antibody fragments (I and III) 
In order to compare affinities of antibody fragments, small amounts of pure 
enantiomers a or d were conjugated to bovine serum albumin (BSA) via the 
same linker molecule that was used for racemic mixture. The conjugation with 
the pure a-enantiomer failed repeatedly, probably due to the steric hindrance. For 
the affinity measurements we therefore had only the d-BSA conjugate, which 
was used for the d-enantiomer specific ENA5His and its affinity mutants. The 
affinity constant for ENA11His has not hitherto been determined. 
Nieba et al., 1996 studied how the values obtained from BIAcore measurements 
(based on surface plasmon resonance) corresponded to the affinity measurements 
in solution. They observed great discrepancies between the values. Rebinding and 
avidity effects influenced the values obtained by kinetic measurements in 
BIAcore. Furthermore identical surface coatings were difficult to obtain. Higher 
affinity constant values from BIAcore compared to homogeneous assays were also 
observed by Borrebaeck et al., 1992. However, competition BIAcore can be used 
for affinity ranking of antibody fragments. 
We used competition BIAcore to perform the affinity ranking of the ENA5His and 
its affinity mutants and to compare the results with the enantioseparation 
experiments in the small scale affinity columns. Fab-fragments are monovalent, 
obviating the avidity problem. The regeneration step after each run was optimised 
so that the same surface could be used for all constructions, thus eliminating the 
uncertainty caused by dissimilar binding surfaces. In general the antibody 
concentration should be close to the estimated KD while the concentration of the 
competing hapten is varied. However, due to the lack of estimates of the affinities 
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of the mutants we used a 100 nM antibody concentration for all constructs, even 
for ENA5His with an affinity of 1020 nM. 
IC50-values of a- and d-enantiomer reported for ENA5His and its affinity 
mutants (Table II, Appendix III) were measured with the same amount of 
antibody fragment, the same surface of immobilised d-BSA and the same 
conditions and data analysis in order to make comparison between them more 
reliable. Details of the measurements with the BIAcore are presented in 
Appendix III. Comparison of the mutants was made in order to select the most 
promising candidate for the affinity column experiments and for the construction 
of a double mutant. Surface plasmon resonance (BIAcore) was also used to 
visualise the association and dissociation behaviour of the mutated Fab-
fragments to the parental ENA5His. In Figure 5, Appendix III, an overlay plot of 
the binding curves shows the differences between mutants and wild type Fab 
both in association and dissociation phases. The most dramatic difference was 
seen in Tyr96Val mutant, which reaches the equilibrium earlier than other 
mutants and the dissociation is much faster.  
The other goal in the mutagenesis study was to maintain the specificity of the 
recognition between a- and d-enantiomers. The IC50-values for the a-enantiomer 
showed up to 2-fold decrease for some mutants, so the relative affinity 
difference between a- and d-enantiomers was decreased for these mutants. 
However, in each case the affinity difference was high enough for efficient 
separation of the enantiomers in column format. 
The efficiency of the elution of the bound d-enantiomer with 40% methanol-
PBS, pH 7.4 was compared between mutants (Table III, Appendix III). Both the 
overlay plot and the competitive analysis made by BIAcore were in good 
agreement with the elution efficiency studies, except for the mutant Thr97Glu. 
This mutant had wider variation in all experiments, especially in column 
performance, and was therefore not used in later studies. The double mutant 
Trp33Ala/Tyr96Val showed 2-fold reduction in affinity in BIAcore 
measurement compared to Tyr96Val and in column experiments the bound d-
enantiomer was eluted efficiently already at 35% methanol-PBS, pH 7.4. 
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3.5 Recombinant antibodies in affinity matrices (I, III and IV) 
Due to the main interest in the d-enantiomer all the fractionation and the 
analytical studies in columns were performed in order to purify or analyse the d-
enantiomer. Small-scale columns (300500 µl) were used to study the 
specificities and the fractionation properties of the Fab-fragments. First the 1:1 
racemic mixture of a- and d-enantiomers was applied to the ENA5His column. 
The d-enantiomer was bound to the antibody support, whereas the a-enantiomer 
was found in the flow-through (Figure 2 a, Appendix I). ENA11His columns 
behaved in an opposite manner (Figure 2 b, Appendix I). From the racemic 
mixture of the b- and c-enantiomers both antibodies bound only the b-
enantiomer. This suggests that the chiral carbon responsible of the different 
configurations and the specific binding is most probably different for these 
antibody fragments. 
3.5.1 Immunoaffinity chromatography for preparative fractionation 
of enantiomers (I and III) 
The affinity supports of both wild-type antibody fragments, ENA5His and 
ENA11His, were made by immobilisation via a histidine tag to the metal affinity 
support. The conditions for the enantioseparation were screened first with the 
ELISA and small scale columns as described in Appendix I. Efficient binding 
was obtained at 2% DMSO-PBS, pH 7.4 and the bound enantiomer was 
efficiently released by increasing the pH to 11.6. However, 45% of the Fab-
fragments was co-eluted and the total loss of binding capacity was 8590%, 
possibly due to inactivation of the remaining antibodies at high pH. Reactivation 
of antibodies by extensive incubation in PBS, pH 7.4 might have restored at least 
partially the binding activity of the immunosorbent as reported by Delaunay-
Bertoncini and Hennion, 2004. However, in preparative scale fractionation 
applications there is a need for repeated runs with rapid turnover and such a long 
reactivation is not a viable approach. Therefore a search was made for milder, 
non-denaturing elution conditions. 
The antigen-antibody interaction can be disrupted by different means including 
pH, buffer composition, temperature, chaotropic agents and organic solvents or a 
combination of these elements. We studied the effect of organic solvent, due to 
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the fact that in high concentration the diarylalkyltriazole is poorly soluble in 
water. The d-enantiomer was efficiently eluted from the ENA5His-support with 
5575% methanol-PBS, pH 7.4. However, antibodies were partially denatured in 
these conditions. The best results were obtained with 55% methanol-PBS, which 
caused 30% decrease in binding capacity in the next round of separation. By 
contrast ENA11His efficiently released the bound a-enantiomer at 30% DMSO-
PBS, pH 7.4 and 40% methanol/ethanol-PBS, pH 7.4 without dramatically 
losing its binding capacity in subsequent rounds of enantioseparation. 
An automated and larger scale separation system was applied to study in more 
detail the reusability of the ENA11His columns. The maximum binding capacity 
was determined experimentally by loading an excess of racemate to the column 
and measuring the amount of eluted a-enantiomer. Reusability tests were 
performed by using racemate having this experimentally determined maximum 
amount of a- enantiomer and an equimolar amount of d-enantiomer in order to 
observe even slight decreases in the binding capacity. During the first cycles the 
binding capacity decreased ca 20%, reaching a steady state at which the 
ENA11His columns bound 4145% of the theoretical maximun of the a-
enantiomer. In theoretical maximum one mole of antibody binds one mole of 
enantiomer. In the case of ENA11His the binding ratio was 1:0.4. The capacity 
was reduced after the first elution cycle, most probably because some of the Fab-
fragments did not have the disulphide bond between the heavy and the light 
chain. Chains joined only by non-covalent interactions are more likely to be 
sensitive to solvent elution, due to the possible dissociation of the heavy chain 
from the support. The dissociation of the heavy chain does not however explain 
the generally low binding capacity of the ENA11His in affinity columns. 
Preliminary results showed that ENA11His also has affinity for the d-enantiomer 
and the possible competition between enantiomers might explain the reduced 
capacity. Further studies of the binding specificity of the ENA11His will 
elucidate this phenomenon. In the case of ENA5His the theoretical and the 
experimental binding capacity were consistent with each other. Due to the 
decreased binding capacity in the column, the possible cross-reactivity and the 
difficulty of determining the affinity data for ENA11His, the mutagenesis study 
was focused on ENA5His. The aim was to use these low affinity mutants to 
determine the functional affinity range of antibodies in affinity supports. This 
goal was not achieved with this first set of mutants because the critical low 
affinity was not reached even with the double mutant. Additional mutants have 
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however been made and preliminary results suggest even lower affinities (data 
not shown). In the future cross-reactivity studies could also be used to determine 
the specificity-capacity correlation in affinity columns.  
Two different elution modes, gradient and step-wise, were tested for the 
ENA11His column. Elution volumes were 25 and 10 bed volumes, respectively. 
The result shows that the elution volume and thus solvent consumption can be 
adjusted by the mode of elution. However, the rapid change in conditions caused 
about 10% decrease in the binding capacity of ENA11His after 20 cycles, 
whereas no decrease was observed in the columns eluted with the gradient.  
In Appendix III the immunoaffinity columns made of the single mutant 
ENA5HisTyr96Val and the double mutant ENA5HisTyr96Val/Trp33Ala were 
studied in a similar manner as the ENA5His and ENA11His in Appendix I. The 
reduced affinity made it possible to use the affinity supports of immobilised 
mutants for twenty cycles of enantioseparation without significant loss in 
binding capacity. Both columns were functional after six months of storage in 
PBS, pH 7.4 in +4 °C. These results with the affinity mutants confirmed that 
affinity supports of recombinant antibody fragments can be used to fractionate 
enantiomers of a racemic mixture in a repeated runs. Using anti-
diarylakyltriazole antibody as an example we calculated that one litre of 
bacterial culture supernatant provided enough antibody to make a column for 
enantioseparation of 10 mg of drug candidate in 20 cycles of fractionation. This 
amount is sufficient for the early phases of drug development (Appendix III). 
Affinity columns made of antibody crystals offer an interesting benefit over 
traditional immunoaffinity supports. ENA5His was also used to set up a 
chromatographic system based on cross-linked antibody crystals (Vuolanto et 
al., 2002, not included in this thesis). The goal was to decrease the size of the 
affinity columns by using antibodies in the most dense packing format. Affinity 
columns made of antibody crystals were able to fractionate the enantiomers. 
However, only 3350% of the theoretical maximum of the binding capacity was 
achieved (Vuolanto et al., 2003, 2004). The decrease may have been due to the 
crystallisation, subsequent cross-linking or restricted diffusion inside the 
crystals. The ENA5His used in these studies had two lysines in the binding site, 
which may have reacted with the cross-linking agent glutaraldehyde. Antibody 
engineering could be used to study the effect of lysine residues at the binding 
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site on the binding capacity of the cross-linked antibodies. Antibody engineering 
also opens interesting possibilities to design an antibody framework with 
improved crystallisation properties (Wingren et al., 2003). Different approaches 
of molecular engineering can be used to promote crystallisation of proteins 
(Derewenda, 2004). By combining the crystallisation-prone framework to CDR-
libraries, it might be possible to facilitate the present tedious experimental 
screening for crystallisation conditions. This approach would be especially 
useful in applications such as affinity chromatography, in which the quality 
demands of the crystals are not as strict as in protein structure determinations. 
3.5.2 Antibody-based solid-phase extraction as a pretreatment 
method for the analysis of enantiomers (IV) 
The aim was to develop a simple antibody-based sample treatment method 
applicable in high-throughput format. The quality of the sample treatment 
method is crucial to the reliability of the whole analytical procedure. In many 
methods used at present an internal standard is used to compensate the poor 
performance of the analytical systems. 
ENA5His and one of its affinity mutants ENA5HisTyr96Val were used to set up 
the solid phase extraction experiments. They both bind efficiently the d-
enantiomer from the sample but due to its faster dissociation the ENA5Tyr96Val 
was used in most experiments to ensure the efficient release of the enantiomer in 
lower volume from the antibody support. The conditions used in previous 
affinity columns for these antibodies were not directly applicable to the solid 
phase extraction method. Whereas the antibodies in the column were able to 
bind the d-enantiomer from the racemate in 2% DMSOPBS, pH 7.4 in 1:1 
molar ratio, the binding in SPE-format was less efficient. Two and four molar 
excesses of Fab-fragments were needed for quantitative binding of the d-
enantiomer from the PBS-buffer and plasma, respectively. Although the SPE 
functions according to the same principles as liquid chromatography, the number 
of theoretical plates is limited.  First both 96- and 384-well plates with a filter at 
the bottom of each well were tested. The 25 µl of the immunoaffinity support 
forms flat disk at the bottom of the 96-well plate, whereas the same amount of 
support forms a tiny column in a 384-well plate. The spurting of eluents was 
extensive for the 96-well plates due to the different design of the drip director 
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and the recoveries from the 96-well plate experiments were not as good as in the 
384-well plate studies.  Therefore all the statistical experiments were made with 
the 384-well plates. 
SPE was here developed as a sample preparation method for direct mass 
spectrometric (MS) analysis. Throughout the whole procedure the specific 
demands of MS-analysis were kept in mind. Mass spectrometry is a sensitive 
analytical system. The analyte must be in a volatile buffer and solvent. The 
unspecific binding of impurities of the sample matrix to the SPE followed by 
their co-elution can impair the MS-analysis by increasing the background noise 
and thus reducing the sensitivity (Figure 5). Impurities may even suppress the 
signal of the target analyte (Ferguson et al., 2001, Rolcik et al., 2002). We used 
a C18-column between the immuno-SPE and MS-analysis in order to avoid any 
interference of possibly co-eluted compounds at this early stage of method 
development. However, the ultimate goal is to develop the methods further 
towards direct MS-analyses. A number of the parameters in sample application, 
e.g. washing and elution, were studied (Table I, Appendix IV). In many research 
reports biological samples have been diluted to buffer, pH has been adjusted or 
some additives have been introduced before applying the sample to the SPE. We 
applied plasma samples directly in order to see whether the sample handling 
time could be minimised by omitting protein precipitation or other additional 
steps such as those mentioned above. For dilute samples (360 ng/ml) the 
application volume was increased five- or tenfold in order to increase the 
response level clearly over the lowest limit of quantitation with a signal to noise 
ratio >10. The results showed that diluted samples can be quantitated by 
increasing the sample volume, due to the ability of the antibody to enrich the 
analyte. 
The efficiency of washes was studied by varying the number of repetitions, 
different volumes and buffer compositions as listed in Table I, Appendix IV. 
The goal of the washing step was to remove the impurities and adjust the 
conditions for subsequent elution. 10 mM ammonium acetate, pH 5.0 was found 
to be the most suitable. Methanol caused additional spurting. EDTA and 
imidazole did not bring any additional advantage when the C18 -column between 
SPE and MS was used at this method development stage. However, in the future 
when the aim is to automate the method this additional step of C18-liquid 
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chromatography will be rejected and more attention must therefore be paid to the 
washing step before the direct injection of the eluate to MS. 
Efficient elution was obtained with 25 mM ammonium acetate, pH 2.8. Addition 
of methanol again caused increased spurting and variance in elution volume and 
was therefore not used. Due to the low concentrations of the enantiomer in 
eluents and the immediate injection to the HPLC(C18)-MS combination, no 
organic solvent was required to keep the analyte soluble before analysis. With 
this system setup the objectives of quantitative binding of the analyte (d-
enantiomer), washing away the low affinity compound (a-enantiomer) and 
efficient elution of the bound analyte were all achieved (Figure 1, Appendix IV). 
The specificity of the binding was studied by determining the possible unspecific 
binding of the d-enantiomer to the plain support and to another hapten binding 
antibody. No binding of the d-enantiomer to cobalt-Sepharose or to anti-
morphine-Fab support was observed. In a second set of experiments we studied 
the co-binding of the other enantiomers (unpublished data). ENA5HisTyr96Val 
was used in tenfold molar excess to avoid any competition between enantiomers. 
A fixed amount of d-enantiomer was used. To this was added an equimolar 
amount of a, b, c or d. The double amount of d increased the response twofold, 
showing that the amount of Fab-fragments was not the limiting factor for 
binding. Most of the b-enantiomer was also bound, which is in good agreement 
with the small scale column results. The addition of a- and c-stereoisomers 
showed no increase in total response. In the future it would be interesting to 
study the correlation of the cross-reactivity between enantiomers and their 
relative binding to antibody support. In some applications the unwanted 
compound, having a slight affinity for the antibody, may be present in high 
concentration and create problems for the purification or analysis of the target 
compound. 
The main objective of this SPE-study was to see how the antibody-based 
extraction meets the challenges of bioanalytics. Six replicates of samples for 
each measurement were used and only complete sets of experiments were 
included in the statistical analysis. The buffer and plasma samples were spiked 
with the d-enantiomer only. Recoveries were 79122% and 80108% for buffer 
and plasma samples, respectively (Table II, Appendix IV). For the first two 
series (3003000 ng/ml, Buffer A) the recoveries were unacceptably high, 
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possibly due to evaporation of solvent before MS-analysis. Avoiding storage of 
samples improved the accuracy of the system. Our results are in good 
compliance with the recoveries reported for C18 supports in 96- and 384-well 
extractions for small molecular weight analytes (Souppart et al., 2001, Rule et 
al., 2001, Shou et al., 2002, Pommier et al., 2003, Svennberg et al., 2003, Kim 
et al., 2004). However, additional value for the antibody support was gained 
from the enantioselectivity. Antibody support was used in this type of set-up for 
the first time and therefore closely related references to evaluate and compare 
our approach are not yet available. 
The recoveries from the spiked plasma samples were in general lower than for 
spiked buffer samples. We used the affinity mutant ENA5HisTyr96Val in all 
experiments to make comparative analysis for buffer and plasma samples. 
However, higher affinity antibody might have retained the d-enantiomer from 
the complex plasma sample more efficiently because the affinity of the antibody 
is crucial for the extraction. In SPE supports for analytical applications the 
repeated use is not an issue and therefore the high affinity antibodies could also 
be used. According to Rule et al. (2001), frothing decreases the binding 
efficiency of plasma samples in low affinity supports. High affinity supports are 
likely to decrease this effect. 
The precision (RSD%) value expresses how close the individual measurements 
are to each other. For bioanalytical methods RSD values below 15% are 
acceptable (FDA: Guidance for industry. Bioanalytical method validation, 
2001). In our system the experiments with spiked buffer generally showed good 
precision values. However, two out of eight plasma experiments had too high 
values. Extraction volumes were checked but they were not the cause of 
variance. Comparison of the precision values of ENA5His and ENA5His 
Tyr96Val supports might indicate whether the precision could be influenced by 
increasing the affinity of the support. Accuracy values describe how close the 
measured values are to the nominal value. For bioanalytical methods, accuracies 
should be below 15% (FDA: Guidance for industry. Bioanalytical method 
validation, 2001). Most of the buffer samples showed good accuracy, whereas 
many of the plasma samples had too high values. Improvements in recovery 
would also increase the accuracy of the system in this case. The limit of 
quantitation was 0.01 µg/ml for MS-analysis of the standard curve with signal to 
noise ratio of >10. The linearity for the whole system was determined by spiked 
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buffer samples over the range 0.033 µg/ml. The correlation coefficient r = 
0.999 was very good. The measured individual values deviated from the 
calculated ones by 0.37.8%. The individual measurements of the lowest 
concentrations had the highest deviation, as usually expected. 
Our study is the first example of the use of recombinant antibodies in a 384-well 
solid phase extraction system. Although these primary results appear promising, 
much effort needs to be put into the further development of the system. 
Examples of other analytes, as well as a systematic study of the affinity and 
specificity requirements of antibody fragments, are needed to evaluate immuno-
SPE in a high-throughput format. The design of the extraction device is also 
very important. In the 384-well format the wells are long and narrow, which 
makes the sorbent form a micro-scale column. The insertion of sorbent and the 
sample application should avoid the possibility of creating plugs caused by air 
bubbles. Frits could also be added to the top of the sorbent to prevent floating of 
the sorbent during sample application, washes and elution (Fisk et al., 2003). 
Cross-contamination between the wells is a problem that becomes more serious 
as the wells get smaller and closer to each other. Careful design of drip directors 
and collection plates in the 384-well format is essential to prevent 
contamination. Drops must become very small and/or be directly guided to the 
bottom of the collection well in order to prevent the formation of large droplets 
plugging the upper part of the collection well. With the plates used in our 
experiments this plugging phenomenon was occasionally observed. The 
possibility to modify the surface properties of the plastic material in order to 
prevent liquid plugs should also be evaluated. In addition, further development 
could be targeted to optimising the support material. The cross-linked agarose 
used in our experiments has ion exhange properties, causing unspecific binding 
of e.g. proteins from the biological samples. Whether the storage of 
immunosorbents is preferred in wet or dry conditions is also an important issue 
to be examined. 
3.6 Immobilised antibody fragments in nanomembranes (II) 
New strategies for fractionation of the enantiomers with enantioselective 
antibodies using nanomembranes (Appendix II) and nanotubes (Mitchell et al., 
2002) have been developed in collaboration with Prof. C. Martins group in the 
  69 
University of Florida. Lakshmi and Martin (1997) reported enzyme-based 
nanomembranes capable of transporting the substrate of the immobilised 
apoenzyme across the membrane towards the lower concentration of the 
substrate, a phenomenon called facilitated diffusion. However the system was 
restricted to the particular enzyme and its substrates or related compounds. 
Finding a suitable specificity, success of cloning and production (or isolation), 
the dimensions of the protein, inactivation of the catalytic activity and the way 
of immobilisation may vary a great deal between different enzymes. Our idea 
was to use antibody fragments instead of enzyme in order to make the system 
more versatile. These natural binding proteins can be obtained against wide 
variety of molecules. Antibodies share a common structure, and rather well 
established production and purification approaches can be applied to speed up 
the construction of nanomembranes with different specificities. Antibody 
libraries offer a remarkable potential to obtain new specificities.  
Antibody-based nanomembranes were developed to separate a- and d-enantiomers 
by facilitated diffusion. The system is based on transient binding of the hapten to 
the antibody and the principle mimics partition chromatography. We used the 
ENA11His affinity chromatography support described in Appendix I for the 
development of suitable conditions for the partition chromatography in isocratic 
conditions. ENA11His was chosen due to its lower affinity and it was possible to 
develop a fractionation method based on partition for this fragment. The ENA5His 
affinity mutants were not yet available at the time of system set-up. Due to the 
poor water solubility of the hapten the main efforts were targeted to adjusting the 
affinity of the antibody with the DMSO-solvent so that the ENA11His would bind 
the hapten specifically but in a reversible manner. Methanol and ethanol were not 
assayed because the facilitated diffusion takes such a long time that the possible 
evaporation of solvent would create unstable conditions and affect the transport 
across the membrane. We found out in column experiments that at 1520% 
DMSO in PBS, pH 7.4 the a- and d-enantiomers could be separated according to 
the principles of partitioning. With higher concentration of DMSO the 
chromatograms of these two enantiomers overlapped and with lower concentration 
of DMSO the d-enantiomer was bound to the column and a change in conditions 
was needed to elute it quantitatively from the column. 
Membrane construction, Fab-immobilisation and facilitated diffusion studies 
were performed at the University of Florida in Prof. C. Martins group. The 
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membranes were based on alumina, having a highly organized array of 
cylindrical pores (Figure 10). The properties of the membranes can be adjusted 
by varying the conditions of anodisation during growing the membrane. The 
strength of the voltage determines the diameter of the pores and the thickness of 
the membrane corresponds to the duration of the anodisation. In these first 
experiments pore sizes of 20 and 35 nm were used and the thickness of the 
membranes was 3540 µm with 2.12.3 × 1010 pores/cm2. The silica nanotubes 
were deposited to the pores of the alumina membrane with a sol-gel template 
synthesis method. Before immobilising the antibody fragment these nanotubes 
were derivatised with a reactive trimethoxysilylpropyl aldehyde. Aldehyde 
carbonyl groups at the inner surface of the nanotubes react with the surface 
exposed amino groups, mainly lysines, on a Fab-fragment. 
 
Figure 10. a) An atomic force micrograph of the surface of an alumina 
membrane. b) A cross-section scanning electron micrograph picture of the 
alumina nanomembrane. Even-sized pores are organised in arrays. Pores 
continue as nanotubes, which extend throughout the membrane. (Pictures 
provided by L. Trofin and C. Martin, University of Florida). 
Nanomembranes between the chambers for feeding and receiving solutions were 
used to separate enantiomers of a diarylalkyltriazole. Antibody-assisted, 
facilitated diffusion transported the enantiomer across the membrane towards the 
lower concentration. The a-enantiomer, that has higher affinity for the 
immobilised antibody, was transported across the membrane 4.5 times faster 
than the other, d-enantiomer, having lower affinity. Graphical presentation of the 
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separation of the enantiomers by the antibody nanomembrane is presented in 
Figure 11. 
Figure 11. A graphical presentation of an antibody-based nanomembrane. The 
diffusion of the enantiomers from the feeding solution through the membrane to 
the receiver solution depends on the specificity and affinity of the immobilised 
antibody (magenta). The high affinity enantiomer (green) diffuses faster through 
the membrane than the low affinity enantiomer (yellow). (Picture provided by 
Janne Turunen. ) 
Two parameters are important for the function of the nanomembranes: the 
efficiency of the transport (flux) and the selectivity. Increase in the pore size 
increases the flux but decreases the selectivity. The higher the concentration of 
the feed solution, the better the flux but at the expense of selectivity. Most of the 
parameters influencing the diffusion have opposite effects on the flux and the 
selectivity. The affinity and the specificity of the antibody are important 
parameters. In this set of experiments the affinity was adjusted with the amount 
of DMSO. At lower concentration (10% DMSO) the transport of the a-
enantiomer across the membrane is faster and more selective than at 30% 
DMSO, where the flux is decreased to the level of passive diffusion and no 
selectivity between the two enantiomers is observed (Appendix II, Figure 3). 
These results are in good compliance with the column experiments in which 
30% DMSO elutes the bound enantiomer. The selectivity of the facilitated 
FEEDING SOLUTION
Racemic mixture RECEIVER SOLUTION
Transported enantiomer
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diffusion would probably be improved by increasing the specificity of the 
antibody.  
In Appendix II the principle of the proof-of-concept study of the facilitated 
diffusion in antibody-based membranes is presented for the first time. The 
highest selectivity coefficient (α = 4.5) and flux (17 nmol cm-2 h-1) were 
obtained with 20 nm and 35 nm pore sizes, respectively. In order to utilize 
antibody-based membranes further, basic research is needed to determine the 
extent to which the properties of an antibody fragment influence the system. 
Antibodies with varying affinities and cross-reactivities might be used to study 
the range of affinity and specificity needed for optimised separation. The 
possibility to specifically transport the desired compound from crude mixtures 
would also be interesting and important to study. 
By solubilising the alumina membrane the individual antibody-containing 
nanotubes can be collected and used to bind one enantiomer from the solution 
and release it in dissociating conditions (Mitchell et al., 2002). Such nanotubes 
also have a potential in other applications such as capsulation of enzymes and 
drug delivery. Both surfaces of the tubes can be functionalised separately and the 
tubes can be constructed from various materials with desired properties such as 
ruggedness or biodegradability. Research in the field of nanomembranes,  
-particles and -tubes is very intense and different materials and fabrication 
methods are under development. For a recent review of biotechnological 
applications of nanotubes and membranes see Martin and Kohli (2003). 
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4. Conclusions and further perspectives 
Enantioselective antibodies can be used in various applications due to their 
ability to specifically bind only one enantiomer in the presence of the other. 
Separation and analytical needs of different enantiomers are mainly related to 
exogenous synthetic compounds such as chiral drugs and other organic 
molecules. Because of the synthetic origin of the enantiomers the separation and 
analytical techniques for the enantiomers have hitherto been developed mainly 
from the chemical point of view, using methods such as fractional 
crystallisation, chemical derivatisations and non-specific chiral chromatography. 
Some examples of enantioselective poly- and monoclonal antibodies have shown 
how the exceptional binding specificities and affinities of antibodies could bring 
additional advantage over traditional chromatographic methods. 
In this thesis the applicability of recombinant antibody fragments in separation 
and analysis of enantiomers of a chiral drug was studied. The enantiomers in 
general have unique characteristics and have therefore specific needs for 
purification, fractionation and analysis. As shown in this work the antibody 
fragments can be used  to construct immunoaffinity chromatography supports 
and antibody-based membranes for the fractionation purposes. One litre of 
culture supernatant provided enough antibody fragments for the fractionation of 
enantiomers needed at the early stages of drug development. 
Antibody fragments were also used for the first time in solid-phase extraction 
supports as a sample preparation method prior to the analysis of the enantiomers. 
The 384-well plates used in this study are a potential format for high-throughput 
sample preparation. Miniaturisation and high-throughput approaches are one of 
the major trends in the pharmaceutical industry. The early selection of antibodies 
against drug candidates would allow both the small scale preparative purification 
and analysis of drug compounds already in the early phases of drug 
development. The methods developed here for the enantiomers are also directly 
applicable to other low molecular weight compounds. 
The limited availability of antibodies recognising small organic molecules has 
restricted the use of anti-hapten antibodies in chemical and pharmaceutical 
studies. The present requirement of sometimes difficult and tedious linker 
synthesis for the hapten prior to conjugation and selection of specific antibodies 
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is an unfortunate disadvantage. The most demanding task in the future will be 
the development of selection methods for native, unmodified haptens. Another 
clear future need is further optimisation of the antibody frameworks to meet the 
requirements of hapten applications. Much research has already been done to 
improve expression, stability and immobilisation. Stability is a very important 
factor both in storage and in assay conditions, which, in the case of anti-hapten 
antibodies, may require the use of organic solvents. Dry storage of the 
immobilised antibody fragments is also important factor to be studied. Ideal 
frameworks could be common templates for synthetic or combinatorial libraries 
providing different anti-hapten specificities. 
In addition to the methods developed in this thesis, interesting emerging 
technologies such as antibody crystals and isolated nanotubes may open new 
possibilities for utilisation of recombinant antibodies. Recent developments in 
antibody technology, including antibody libraries and advanced selection 
methods for obtaining new specificities and antibody engineering for improving 
the properties, greatly enhance the possibility to evaluate more deeply the 
recombinant antibodies in stereochemical applications. 
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